A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer

Carlos G. Acevedo-Rocha[1,2], José A. Munguía-Moreno[3],
Rodolfo Ocádiz-Delgado[3] and Patricio Gariglio[3]
[1]Max-Planck-Institut für Kohlenforschung, Organische Chemie
[2]Philipps-Universität-Marburg, Fakultät für Chemie
[3]Departamento de Genética y Biología Molecular,
CINVESTAV-IPN
[1,2]Germany
[3]Mexico

1. Introduction

The 20th century witnessed a great development of genetics and molecular biology, laying the foundations for a new era in medicine. The elucidation of the mechanism of heredity, for example, helped us understanding the connection between cells, chromosomes, DNA and the genetic code, an historical journey to the center of biology (Lander & Weinberg, 2000). This process strongly consolidated when "the central dogma of molecular biology" (Crick, 1970) was proposed long time ago, whereby the genetic information flows from DNA to RNA to protein. Since then, however, our understanding in the molecular and cellular organization, as well as physiology of living systems has radically changed, partially challenging the validity of the central 'dogma'– by the way, dogma strictly means a belief that people are expected to accept without any doubts, a word to be expectedly seen outside the scientific method lexicon – of molecular biology (Shapiro, 2009). The main paradigm is that cells are able to make decisions based on actively sensing their environment; hence, information processing in living systems can be regarded at least bidirectional. In any case, the recent sequencing of the human genome is a great milestone (Human Genome Sequencing, 2004), whereby the language of the "common thread of humanity" in this new medicine era is just "the end of the beginning" (Stein, 2004).

Genomics studies the total DNA sequence of an organism. Of the approximately 3,000 million base pairs that comprise the human genome, only 1% was firstly estimated to correspond to as low as 25,000 proteins (Southan, 2004), a number that has been changing since the initial sequence drafts of the Human Genome Project (HGP). One motivation behind genome-sequencing projects is the assumption that the nucleotide sequence of an organism provides a description of the genes, its products and interaction networks that orchestrate programs like those sustaining the metabolic activity of a cell or deploying a body plan. However, new discoveries in transcriptome functions significantly expand—and even challenge—the classical concept of the gene and how post-transcriptional molecular events are becoming key to understand gene regulation in higher eukaryotes.

The success of the HGP has provided a blueprint of genes encoding the entire human protein set potentially expressed in any of the approximately 230 cell types comprising the human proteome. Considering that both the current and sometimes limited knowledge of only two-thirds of the 20,300 protein-coding human genes mapped through the HGP is at hand (Legrain *et al.*, 2011), the recently launched Human Proteome Project (HPP) aims to provide for the remaining one-third of proteins experimental evidence related to abundance, distribution, subcellular localization, functions, and interactions (Bustamante *et al.*, 2011).

In the current "post-genomic era" scientists aim not only to build a catalog of all genes, but also to translate the knowledge obtained into benefits for humanity (Collins *et al.*, 2003). By examining tumors at the genomic, transcriptomic, and proteomic levels, for instance, it is possible to better understand cancer biology and improve patient care, diagnosis, prognosis, and therapy (Lin & Li, 2008). Importantly, one key development that has emerged between the interface of the HGP and the HPP is the area of functional genomics or transcriptomics, which aims to assign a function to all transcripts. But this is not a trivial task because talking about transcriptomes involves considering these as entities as diverse as the cell types, developmental stages, environmental conditions and pathological states that an organism harbors or faces. Therefore, we must include a global vision for the process of transcription, i.e. the process by which information contained in DNA is converted (or transcribed) into RNA and how this process is regulated by protein(s) (Fig. 1).

Importantly, it should bear on mind that 57% - a scalable number up to 90% (Costa, 2010) - of the genome is transcribed into RNA but does not code for proteins (Frith *et al.*, 2005). Moreover, very recently non-coding RNAs (microRNAs, small RNAs, small interfering RNAs or siRNAs as well as medium and large RNAs) have emerged as key elements in carcinogenesis. The amazing complexity of the transcriptome and its expansion (Mendes Soares & Valcarcel, 2006), has led to scientists eager to hunt transcriptomes. Fortunately, there are tools to examine the expression of genes at many levels, allowing us to globally understand complex diseases like cancer.

The current manuscript introduces the most common techniques to study the transcription of the 1% protein-coding genes encoded in the human genome, followed by a review of microarray studies that had provided invaluable information of the carcinogenesis of cervical cancer (CC), the most and second most common cancer disease in women from the developing and developed world, respectively. The integration of all this information is very important to not only understand CC from a global perspective, but also to identify key tumor markers that could help for CC diagnosis, prognosis and/or therapy, as discussed in the last part of the manuscript. As for cancer progression involving noncoding RNAs – importantly considered the "masters of regulation" (Costa, 2010), the reader is encouraged to read an excellent recent review (Gibb *et al.*, 2011).

Importantly, CC is largely associated to Human Papillomavirus (HPV) infection, from which there are over hundred types but of these 40 infecting the genital tract and 15 of high-risk related to the development of CC. Thus, HPV is a common sexually transmitted agent after a woman starts her first sexual relationship and responsible of *ca.* 30% of the global cancer burden associated to infective agents (20% of the total) (zur Hausen, 2009).

Fig. 1. Role of transcription in the central 'dogma' of molecular biology. According to this 'dogma', the genetic information flows from DNA to messenger RNA (mRNA) to proteins. The gene CDKN2A/p16INK4a, for example, is located at position "21.3" of the short arm of the human chromosome 9, which resides inside the nucleus. Upon activation by the transcription factor (E2F1), its mRNA is transcribed and the corresponding proteins are translated in the cytoplasm (CDKN2A encodes three but only two variants are displayed). The interplay between the genome, transcriptome and proteome is oversimplified.

2. Probing the transcriptome

The relationship between a particular molecule and cellular phenotype has allowed us to better understand the molecular mechanisms of complex diseases such as cancer. In the course of molecular biology many useful techniques to analyze DNA, RNA and proteins were developed. For about half century, reasonably, the practice of molecular biology was comfortable with its reductionism; however, in the coming era of genomics, the tendency to probe in a single experiment hundreds or thousands of biomolecules allows us talking of two mechanisms: (i) The "reductionist mechanism" employs tools to analyze one or few different molecules in a single experiment; it is a slow but comprehensive conclusions can be reliably obtained; (ii) The "holistic mechanism" allows the assessment of thousands of different molecules in a single experiment; it is a fast mechanism but the obtained

hypotheses remained to be tested (Coulton, 2004). While single gene analyses gradually shifted towards large mutational screens and complete genome mapping, whole genome sequencing moved towards bioinformatics with exhaustive functional genomics and proteomics data. Systems biology aims to understand this complexity. Ironically, the holism in systems biology has re-emerged out of the traditional molecular biology, carrying with it the *reductionism-holism* debate since the past years (Gatherer, 2010). Interestingly, it has been boldly argued that traditional molecular biology represents a greedy reductionist approach (to some authors a naively reductionist one) that requires either extensive complementation from, or even replacement by systems biology. However, as we discuss along the text, it is more meaningful to combine both approaches.

The study of transcription is important because the levels of mRNA transcripts in a cell correlate frequently with the expression levels of the corresponding proteins. There are several techniques used in transcriptomics, which are based on gene amplification by the polymerase chain reaction (PCR), hybridization and sequencing. All these tools permit analyzing differential expression, and determine what transcripts are mainly expressed in cancerous tissue in comparison with normal tissue and *vice versa*. This is important because knowing what and how genes are differentially expressed suggests that these may play an important role in carcinogenesis. This scenario can be found in the case of proto-oncogenes and anti-oncogenes (or tumor suppressor genes) that promote and prevent cell growth, respectively. In other words, the levels of expression of many oncogenes (normally known as proto-oncogenes) may be very high and the levels of expression of tumor suppressor genes may be low. Following the reductionist and holistic classification, the most common techniques used in transcriptomics can be classified into high, medium, and low performance, with respect to its ability to analyze different molecules in a single experiment.

2.1 Low-throughput techniques

One of the first developed methods to detect a mRNA transcript was *in situ* hybridization (ISH) (Harrison *et al.*, 1973). ISH requires labelling either fluorescently or radioactively a RNA or complementary DNA (cDNA) corresponding to the transcript of interest. Through the formation of hybrid cDNA:RNA or RNA:RNA duplexes, the amount of the specific transcript can be determined as well as its cellular position can be localized. Thereafter, the popular technique Northern Blot (NB) was developed. NB uses a labeled probe that recognizes the transcript of interest in a similar manner to the ISH, but the hybridization is performed on cellulose, because the RNA of a tissue is previously separated by electrophoresis and transferred to a special paper surface. If the transcript of interest forms a hybrid with the radioactively labeled probe, it will reveal the presence of a band in a autoradiography upon exposure (Alwine *et al.*, 1977). Because of its sensitivity, this technique is commonly used in molecular biology. Another similar technique, called ribonuclease protection assay (RPA), is based on hybrid formation between the mRNA of the gene in question and a labeled probe (RNA or cDNA), being the non-hybridized single-strand RNA part degraded by a RNAse enzyme (Berk & Sharp, 1977). This way, the hybrids can be detected because the RNA chain is radiolabelled; this method is 50 times more sensitive than NB (Bartlett, 2002).

Another old technique is subtractive hybridization (SH), which employs single-strand RNA or cDNA labeled probes. Using SH one can remove commonly expressed genes between

two samples (e.g. cancerous and normal tissue) by hybrid formation between cDNA:RNA and identified those differentially expressed genes in a particular tissue (Zimmermann *et al.*, 1980). The tumor-suppresor gene p21WAF1/CIP1, also known as CDKN1A, involved in the negative regulation of the cell cycle as well as the induction of apoptosis, was identified using SH (el-Deiry et al, 1993). Finally, the Retro-Transcription coupled to PCR (RT-PCR) allows the amplification of a cDNA synthesized from a specific mRNA using a reverse transcriptase (Rappolee *et al.*, 1988). RT-PCR can also be applied to tissues (*in situ* RT-PCR) similarly to the ISH but the sensitivity differs: While ISH can detect from 20 to 200 copies of transcript per cell, *in situ* RT-PCR can detect one transcript per cell (Bartlett, 2002). The enormous sensitivity of RT-PCR has allowed the development of a technique to quantify quickly and accurately the amount of transcripts in a given biological sample. It is called quantitative RT-PCR or Real-Time PCR (qRT-PCR) (Bustin, 2000). All these methods mainly based on hybridization and PCR can generally characterize one transcript per experiment.

2.2 Medium-throughput techniques

When a mRNA is converted to cDNA, the fragments obtained can be cloned or inserted into a vector (plasmid), which can be introduced into bacteria to obtain many copies of the transcript. At the end, the fragment of interest must be sequenced. In this way, various types of sequences can be generated: A EST (Expressed Sequence Tags) corresponds to an arbitrary portion of a cDNA sequence, i.e. a random sequence that allows identification of a transcript (Adams *et al.*, 1991), whereas "ORESTES" (Open Reading Frame Expressed Sequence Tags) contain an open reading frame, which generally corresponds to a central portion of the cDNA sequence (Dias Neto *et al.*, 2000); it is also possible to alternatively clone the entire sequence of cDNA without tag (Strausberg *et al.*, 2002). Importantly, all these partial or complete cDNA sequences had enabled the characterization of large numbers of transcripts and their differential expression depending on their frequency and tissue of origin.

Similarly, the techniques of Differential Display (DD) and Representational Differential Analysis (RDA) permit the identification of differentially expressed transcripts e.g. coming from different sources or coming from the same source but subjected to different conditions. DD is essentially based on a series of RT-PCR amplifications where the transcripts of two samples are fluorescently or radioactively labeled, compared by electrophoresis, selected and finally sequenced (Liang & Pardee, 1992). The RDA technique is based on SH and RT-PCR, so that common transcripts between two samples are removed after the formation of hybrid cDNA:cDNA and genes only expressed in a tissue are amplified in a sensitive and accurate way (Hubank & Schatz, 1994). Since both techniques are of easy accessibility and use, their use has allowed the identification of many genes altered in cancer (Liang & Pardee, 2003; Hollestelle & Schutte, 2005). For example, while the Cyclin G was identified using the DD technique (Okamoto & Beach, 1994) the anti-oncogene PTEN was characterized through RDA (Li *et al.*, 1997). The medium-throughput methods basically depend on sequencing and differ from those of low-performance because many transcripts can be characterized at a single experiment, but not as many as when using high-performance ones.

2.3 High-throughput techniques

In general, these methods are based on sequencing and hybridization. Sequencing includes Serial Analysis of Gene Expression (SAGE) and Massively Parallel Signature Sequencing

(MPSS) and, in the case of hybridization, the best example is DNA microarrays. SAGE is similar to the sequencing of ESTs or cDNA clones, but the performance is much higher because in a single vector a lot of small tags corresponding to different mRNAs can be inserted. After sequencing, the abundance of these tags can be measured doing a bioinformatics analysis, whereby the fold expression change of a gene in different tissues/conditions can be estimated (Velculescu *et al.*, 1995). MPSS is similar to SAGE but the main difference is that in the former small tags are attached to microbead arrays, increasing the capacity of the system (Brenner *et al.*, 2000). Although MPSS is similar to SAGE, the later method has been widely used, uncovering many genes with a potential role in cancer (Yamashita *et al.*, 2008), and allowing the identification of known oncogenes such as ERBB2 and EGFR (Polyak & Riggins, 2001; Forrest *et al.*, 2006).

The DNA microarrays are a set of gene sequences (which may correspond to transcripts) arranged on a flat surface. There are two types of DNA microarrays: cDNA microarrays, in which transcripts of interest are amplified by PCR and deposited on sites identified in a paper or small glass slide (Schena *et al.*, 1995) and oligonucleotide microarrays, in which small sequences corresponding to a gene are synthesized and arranged on a particular area of a slide (Lockhart *et al.*, 1996; Singh-Gasson *et al.*, 1999; Hughes *et al.*, 2001). While the former arrays are normally produced in-house by researchers, the latter one are usually obtained from companies, being the most known "Affymetrix". During the experiment, the mRNA of a tissue of interest is firstly converted into cDNA and labeled either radioactively or fluorescently. Then, through the formation of hybrids between the labeled cDNA and the unlabelled cDNA or oligonucleotides attached to the surface, differentially expressed genes between two samples can be identified. Finally, the ratios of frequency can be estimated using different bioinformatics methods. Both cDNA and oligonucleotide microarrays have been widely used, the difference lies in the number of genes per square centimeter: On paper there may be hundreds of genes, whereas in a glass slide it is possible to bear sequences representing up to 10,000 and 25,000 genes in the case of cDNA and oligonucleotide microarrays, respectively. This allows the simultaneous quantification of thousands of gene transcripts in two samples when they are tagged with different fluorophores, for example, if the transcripts from tumor cells are stained with red (e.g. Cy5) and those from normal cells with green (e.g. Cy3), upon locating spots on a cDNA microarray, while the red and green ones would respectively correspond to genes differentially expressed in the tumor and normal tissue, the yellow (and alike degrees of color) would correspond to genes similarly expressed in both tissues. This is usually done on cDNA microarrays because the spots can be compared directly in one experiment, but in the case of oligonucleotide microarrays, the spots are compared indirectly in separate experiments because the detection and analysis methods differ. In either case, the different spot intensities can be transformed into transcript levels present in each sample. The numerical data are analyzed with a computer and mathematical algorithms, allowing various genes to display a characteristic pattern or "Gene Expression Profile" (GEP) related to the phenotype of the different samples. Depending on the intensity in which the various genes from the GEP are expressed, the sample acquires a particular "expression signature".

The transcriptome should study not only the expression of transcripts, but also the DNA sites where transcription factors bind as well as chromatin modifications that regulate gene expression. Chromatin Immunoprecipitation (ChIP) is a old technique to identify genes that can be activated by a protein *in vivo* (Orlando, 2000), but can be of high-throughput when it

is coupled with: i) DNA microarrays (Ren *et al.*, 2000), also known as "ChIP-on-Chip", for instance, many genes that can be activated by the transcription factors E2F have been identified (Bracken *et al.*, 2004); or 2) Sequencing-based techniques like Paired-end di-tags (PET) that is equivalent to SAGE but in contrast to a tag, two gene extremes are joined (Ng *et al.*, 2005). Using ChIP-PET, several TP53-regulated genes have been identified (Wei *et al.*, 2006). TP53 and E2F are the most important transcription factors known in cancer development, activating or deactivating genes involved in cell cycle and apoptosis.

Last but not least, another successful tool combined with microarrays is Laser Capture Microdissection (LCM), which uses a laser beam targeted to specific tissue sections under microscopic control to isolate cell clusters, allowing the molecular comparison of cell populations that are histologically or pathologically distinct but topographically contiguous (Kalantari *et al.*, 2009). The main limitation of this technique, however, is that it requires trained personnel to visually select cell populations of interest. One approach to increase dissection performance is to utilize molecular probes to facilitate the process. Expression microdissection (xMD) is such an example, where an antibody is used for cell targeting in place of an investigator (Tangrea *et al.*, 2004; Hanson *et al.*, 2011). In fact, large numbers of cells can be greatly analyzed by using the recently described SIVQ feature matching algorithm, making possible the development of a high-throughput cell procurement instrument. This approach permits histologically constrained morphologies (e.g. automated selection of only the malignant epithelium of solid tissue tumours) to be acquired in a semi-autonomous fashion, allowing the generation of large, preparative quantities of DNA, RNA, or protein for subsequent high-throughput analysis. In fact, SIVQ–LCM holds unique potential as a discovery tool for molecular pathology, since individual cells with particular computer-defined morphologic features can be microdissected and profiled, thus generation new integrated and composite morphological data types (e.g. morpho-genomics or -proteomics) (Hipp *et al.*, 2011). Importantly, there is increasing evidence demonstrating the necessity of upfront malignant cell enrichment techniques for specific molecular profiles, being especially desirable for clinical trials that require accurate, disease cell-specific molecular measurements (Harrell *et al.*, 2008; Klee *et al.*, 2009; Silvestri *et al.*, 2010). This technique has opened new and promising avenues to molecularly enquire histology and pathology in many fields of cancer research (Fuller *et al.*, 2003; Domazet *et al.*, 2008).

All the techniques mentioned above (Fig. 2) have favorable characteristics, while the high-throughput methods have a great capacity for data management; the low-throughput ones confer higher specificity, sensitivity, and reproducibility. Due to this, high- and medium-performance techniques are complementary, but they must be validated with those of low-performance. These tools have generated much information that should be integrated to extract biological meaning, allowing the complete characterization of the transcriptome of a cell. Indeed, a complete integrative analysis of the cancer transcriptome cannot only be obtained by analyzing the genome, transcriptional networks and the interactome, (Rhodes & Chinnaiyan, 2005), but also by delineating the subtypes of cancer obtained from DNA microarrays with relation to a particular phenotype.

3. A brief overview on microarrays and cancer

Microarrays are one of the most versatile tools used in transcriptomics, whereby many benefits for oncogenomics have been found. For example, thanks to the determination of

Fig. 2. Probing the transcriptome at different performances. a) Upon DNA transcription, messenger RNA (mRNA) molecules can be analyzed in a single experiment: i) For one or few transcripts, low-throughput methods include *in situ* hybridization (ISH), subtractive hybridization (SH), "Northern Blot" (NB), Ribonuclease-Protection Assay (RPA), Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR), *in situ* RT-PCR and quantitative or real time RT-PCR (qRT-PCR). ii) For various transcripts there are medium-throughput tools based on cDNA clones, Expressed Sequence Tags (ESTs), Open Reading Frame ESTs (ORESTES), Differential Display (DD) and Representative Differential Analysis (RDA). iii) For thousands of transcripts, Serial Analysis of Gene Expression (SAGE), Massive-Parallel Signature Sequencing as well as DNA and oligonucleotide microarrays are high-throughput approaches. b) Transcription regulation: To identify Transcription Factors (TF) that bind specifically to DNA sites, one can use Chromatin Immunoprecipitation in a low- (ChIP) or high-throughput manner when it is coupled to microarrays (ChIP-to-Chip) or Pair-End di-Tags (ChIP-PET). These methods are classified according to the holism-reductionism approach.

Gene Expression Profiles (GEPs) using DNA microarrays, a new molecular classification and subclassification, as well as clinical prediction and diagnosis of many cancer (sub)types

have been developed (Macoska, 2002; Ciro *et al.*, 2003; Wadlow & Ramaswamy, 2005). Likewise, new potential markers for therapy have been identified and there is a better understanding of the molecular mechanisms of cancer (Clarke *et al.*, 2004). There are classic studies that have demonstrated the potentials of microarray technology, for instance, one of the first reports was the molecular classification of human acute leukemias using an oligonucleotide microarray (Affymetrix) representing 6817 genes (Golub *et al.*, 1999). In this study, 50 genes were found aid to distinguish between acute myeloid leukemia and acute lymphoblastic leukemia. To validate the gene set, 34 samples were analyzed without knowledge of its type (unsupervised analysis) and classified in their respective type with a high accuracy. This was a very important achievement because the right diagnosis of this cancer is often difficult but essential to discern because an effective treatment relies on an accurate identification of the cancer subtype.

Another classical study was applied on the Diffuse Large-B-Cell Lymphoma since it is known that patients exhibit different prognoses and variable responses to therapy. Using a microarray containing over 18,000 cDNA clones, a GEP with little more than 100 genes and 96 different samples was established (Alizadeh *et al.*, 2000). This pattern allowed the classification of this cancer into two subtypes regarding the status of differentiation of B cells: one similar to germ B cells and other similar to activated B cells *in vitro*. Interestingly, the two subtypes showed a strong correlation with clinical prognosis, which was the best for the subtype bearing germinal B cells. These patients are usually treated with a combination of chemotherapy based on anthracyclines, but if they don´t have a good prognosis then a bone marrow transplantation is rather recommended. Therefore, the GEP of about hundred genes can help to determine what kind of treatment and prognosis a patient should have. Thereafter, this work was validated by using 240 samples that allowed the identification of only 17 genes capable to correlate disease with prognosis (Rosenwald *et al.*, 2002). Similarly, another laboratory studied the prognosis of the same cancer type but whose patients received different treatments, allowing the identification of two groups of patients with different life expectancy for 5 years (72% good versus 12% bad prognosis) using only a predictor of 13 out of 6,817 genes included in a "Genechip" from Affymetrix (Shipp *et al.*, 2002). It is noteworthy that 3 tumor markers were detected in both the 17 and 13 gene predictors developed independently by those laboratories.

The best example of GEPs, nonetheless, has been demonstrated in the prognosis of breast cancer. Using an oligonucleotide microarray of 25,000 and 78 samples of primary breast tumors obtained from patients with negative lymph node status for metastasis, a 70-gene "poor-prognosis" molecular signature was identified (van 't Veer *et al.*, 2002). This signature corresponds to a high probability of developing metastasis in the short term and most likely die. What is interesting about this study is that tumors are not "good" nor "bad" when the disease progresses as was proposed not so long time ago with the clonal model of development (Couzin, 2003); rather, the malignant cell is destined to metastasize very early. Through this genetic signature, experts can decide what patients should receive adjuvant therapy consisting of Tamoxifen (an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen). Shortly after, this study was clinically validated using 217 new samples, which reconfirmed that the signature of 70 genes is the best criterion for deciding whether a patient requires adjuvant therapy or not (van de Vijver *et al.*, 2002).

Since the first two studies were developed using samples from young patients with relatively early tumours from the same institution, it was not clear whether the 70-gene could also be applied to other patients. Interestingly, the TRANSBIG consortium, a network of 28 institutions promoting international collaboration in translational research across 11 countries, independently validated the 70-gene signature using 302 samples from patients from different age groups (up to 61 years) and from 5 different European hospitals (Buyse *et al.*, 2006). Despite its achievements, the same group questioned whether this 70-gene signature could be used as a standard high-throughput diagnostic test, so, using the samples from the first two mentioned reports, they validated a customized mini-array containing a reduced set of 1,900 probes known as the "MammaPrint" (Glas *et al.*, 2006). The "MammaPrint" prognostic assay is currently being validated under the clinical MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) randomized trial that includes 6,000 patient samples from various centers, even though the 70-gene signature has been validated several times in patients with negative (Bueno-de-Mesquita *et al.*, 2009) or positive (Mook *et al.*, 2009) lymph-node status as well as from other populations, including Japanese (Ishitobi *et al.*, 2010). Remarkably, the MammaPrint 70-gene signature, whose genes reflect the hallmarks of cancer (Tian *et al.*, 2010), can be considered as a milestone in the personalized care for breast cancer patients (Slodkowska & Ross, 2009).

4. Microarrays and cervical cancer

The origin of cervical cancer (CC) is linked to the infection of High-Risk Human Papilloma Virus (HR-HPV) mainly type 16 and 18. The genome of these viruses contain 8 viral oncogenes, 2 of which code for the early-expressed oncoproteins E6 and E7 that inhibit the activity of the anti-oncoproteins p53 and pRb, respectively. This way, the oncoproteins deregulate the necessary balance between proliferation and apoptosis, promoting the development of cancer. These imbalances have been studied at the transcriptional level and in a comprehensive manner using microarrays in both clinical samples and cell lines derived from CC with and without therapy. Although there are much fewer reports of microarrays compared to other tissues e.g. for every CC microarray paper, there are 7 for breast cancer (Acevedo Rocha *et al.*, 2007); these few studies have provided invaluable information on the molecular mechanisms of CC.

4.1 Studying carcinogenesis using *in vitro* HPV models

A key event in the development of CC is the infection by HR-HPVs. Using microarray technology, gene expression profiles in cell lines as well as keratinocytes containing HR-HPVs have been assessed (Chang & Laimins, 2000; Nees *et al.*, 2000; Nees *et al.*, 2001; Duffy *et al.*, 2003; Garner-Hamrick *et al.*, 2004; Lee *et al.*, 2004; Toussaint-Smith *et al.*, 2004). Similarly, the overall effect upon infection of cultured human keratinocytes with low-risk HPVs (LR-HPVs) has been described (Thomas *et al.*, 2001). Interestingly, in contrast to HR-HPVs, LR-HPVs induce the overexpression of a larger number of genes from the family TGF-β (Tumor Growth Factor) and apparently, LR-HPVs do not suppress interferon-inducible genes (Thomas *et al.*, 2001). This is very interesting as members of the TGF-β family play a role as tumor suppressor genes (at least at the early development of CC) and interferons are key molecules that counteract viral infections mediated by the immune system. These findings help to explain why the LR-HPVs episomes, conversely to those of HR-HPVs, are easily eliminated in many cases.

Another important event in the carcinogenesis of CC is the integration of viral genomes into the cellular genome. It is known that upon viral DNA integration into the host genome, the E2 protein expression is usually lost. Since E2 normally represses both E6 and E7, its absence deregulates the latter oncoproteins. Using microarrays, the overall effect upon viral genome integration of HR-HPV type 16, 18, and 33 into cell lines and keratinocytes has been determined (Alazawi *et al.*, 2002; Ruutu *et al.*, 2002; Pett *et al.*, 2006). Notably, these studies found that the integration of the viral genome into the host genome is a critical step because, besides the high chromosomal instability of the infected cells, interferon-inducible genes are accordingly activated, thus eliminating the cells containing mainly viral episomes but promoting the selection of the more unstable cells.

In addition, the overall effect of expressing E2 in some cervical carcinoma cell lines has been also determined (Thierry *et al.*, 2004), inducing in some cases cellular senescence or exit to the G0 cell cycle phase (Wells *et al.*, 2003). Last but not least, the general effect of eliminating the gene E6AP, an important gene involved in the E6-mediated TP53 protein degradation, has been also assessed in multiple CC-derived (HPV+) cell lines (Kelley *et al.*, 2005). All the studies mentioned in this section have identified significant changes in the expression patterns of hundreds of genes including cyclins, kinases, oncogenes, and anti-oncogenes; some known to be involved in CC but other previously unknown, so all these gathered information is essential to systematically study the HPV-mediated CC carcinogenesis.

4.2 Studying carcinogenesis using patient samples

To identify key genes in the development of CC several strategies have been followed. Some of them had focused on the progress of the lesions while others had compared their origin, i.e. squamous and/or glandular lesions vs normal tissue. In any case, these studies had allowed the identification of gene expression profiles useful for the molecular classification and subclassification of CC.

In the first attempts to classify CC, an expression profile of only 18 differentially expressed genes involved in apoptosis, cell adhesion, and transcription regulation was found between cervical squamous cell carcinoma (SCC) and normal cervical tissue using a microarray of 588 genes (Shim *et al.*, 1998). In another interesting study, employing a 10,000-gene microarray, 40 genes allowed the classification of 34 samples of patients into a normal and a tumoral group (Wong *et al.*, 2003). Moreover, from the 34 samples, 16 could be sub-classified as patients grade IB and IIB tumors, from which four genes displayed key expression levels in both the previous classification and subclassification, suggesting their role as possible tumor markers (Wong *et al.*, 2003). In a similar analysis but using only 1,276 genes together with 10 samples of SCC and 20 of cervical intraepithelial neoplasia grade 3 (CIN3), a gene expression profile showed that, from all the samples corresponding to CIN3, some correlated with the progression to cancer while others did not, implying the existence of a new subdivision of precancerous lesions histologically indistinguishable (Sopov *et al.*, 2004).

The selection and characterization of tumor samples is critical as this has permitted the establishment of significant gene expression differences between samples from squamous and glandular origin in both normal and pathological conditions (Contag *et al.*, 2004). Obviously, these differences arise by the transcriptional activity of genes particularly expressed in the histological subtypes of CC, but other strategies had also compared the

expression profiles between normal and squamous (Cheng *et al.*, 2002b; Chen *et al.*, 2003; Wong *et al.*, 2006) or glandular (Chen *et al.*, 2003; Fujimoto *et al.*, 2004; Chao *et al.*, 2006) tumor samples. Importantly, with a correct histological characterization of the samples, other factors can also be correlated, for example, using more than 40 samples derived from invasive CC (HPV+), it was found that a high burden of viral DNA correlates with high levels of E6 and E7 transcripts, poor prognosis, genomic instability and overexpression of more than 100 genes related to the cell cycle, from which many were identified as oncogenes and at least 50 target genes for the relevant E2F transcription factor family (Rosty *et al.*, 2005). Although the sample description in other studies has remained considerably poor (Ahn *et al.*, 2004a; Guelaguetza Vázquez-Ortíz, 2005; Santin *et al.*, 2005; Vazquez-Ortiz *et al.*, 2005a; Vazquez-Ortiz *et al.*, 2005b), these also had generated long lists of genes possibly important for the molecular study of CC.

Lastly, there are two more examples displaying the great power of microarray technology as these have enriched samples from cytological screening (Papanicolaou). For instance, by obtaining normal and cancerous cells from a cytobrush and from simple exfoliated cells, it was possible to identify known and potential tumor markers in epithelial cells (Hudelist *et al.*, 2005) and CIN3 lesions (Steinau *et al.*, 2005), respectively.

4.3 Treatment

In the CC treatment, besides surgery there is radiotherapy and chemotherapy. However, it's not possible to predict the individual response of patients. The ability of tumor cells to evade treatments suggests that there are different resistance-induced mechanisms. It is believed that by monitoring the genes involved in the resistance against therapy, will help not only to understand the molecular mechanisms of CC, but also to improve its treatment. Accordingly, depending on the gene expression profiles of tumor samples that indicate sensitivity to radiation or chemotherapy, it could be possible to classify patients, allowing a customized CC treatment (Chin *et al.*, 2005).

4.3.1 Radiation

The survival of patients diagnosed with cervical cancer has been improved by combining radiotherapy and chemotherapy. However, it has been estimated that about 65% of patients can be cured with radiation alone (Usmani *et al.*, 2005) but such patients have not been identified so far and therefore they suffer the unnecessary and lethal chemotherapy effects. The long-term goal of the first report using microarrays in combination with radiotherapy against CC, was to find a GEP that would help deciding whether a patient would benefit or not with this treatment, avoiding in this way chemotherapy (Achary *et al.*, 2000). Using a microarray of 5,776 genes, 70 identified genes allowed the differentiation of two cell lines derived from a single carcinoma, which had been previously characterized as radiosensitive and radiotolerant. Interestingly, some genes were previously associated with a cellular response against radiation, suggesting a key role in therapy resistance (Achary *et al.*, 2000). Likewise, it was possible to classify 19 samples with 100% accuracy in two groups: sensitive and tolerant to ionizing radiation (IR) by using 62 out of 23.000 (Kitahara *et al.*, 2002). Moreover, from the genes identified in the previous study, it was found that low levels of the gene XRCC5, and its corresponding protein Ku80, correlated with a good prognosis in CC patients (Harima *et al.*, 2003). Thereafter, but using instead 35 genes, the same group

classified samples from patients treated with radiation and hyperthermia in two groups: sensitive and tolerant (Harima *et al.*, 2004). Importantly, not only the combined treatment offered a better prognosis than radiotherapy alone, but a long list of genes with a possible role in the molecular mechanisms associated with therapy was obtained.

There are other studies where samples of patients with CC were classified in radiotolerant or radiosensitive (Wong *et al.*, 2003), as well as in different radiosensitivity degrees (Tewari *et al.*, 2005). In addition, *in vitro* studies using human keratinocytes (Chen *et al.*, 2002), cervical carcinoma cell lines lacking HPV (Liu *et al.*, 2003) and harboring HPV type either 16 (Liu *et al.*, 2003; Chung *et al.*, 2005) or 18 (Crawford & Piwnica-Worms, 2001; Chaudhry *et al.*, 2003) have been also useful to improve the understanding of the molecular mechanisms that occur when tumor cells are treated with IR. Moreover, high levels of cyclin D1 mRNA (a molecule that promotes the progression of cell cycle) and low mRNA levels of the "Insulin-like Growth Factor-Binding Protein 2" or IGFBP2 (protein that can inhibit or promote tumor growth in many cancers) (Hoeflich *et al.*, 2001) correlate with a radioresistant phenotype in immortalized human keratinocytes and CC cell lines (Chen *et al.*, 2002; Liu *et al.*, 2003; Chung *et al.*, 2005). Other up-regulated genes, primarily involved in the cell cycle, that were detected in patients and radio-resistant cell lines include GAPDH (Kitahara *et al.*, 2002; Harima *et al.*, 2004), E2F3 (Chaudhry *et al.*, 2003; Liu *et al.*, 2003), DDB1 (Chaudhry *et al.*, 2003; Wong *et al.*, 2003) and ICAM5 (Achary *et al.*, 2000; Chung *et al.*, 2005). However, cyclin B1 and D1 have been determined to be overexpressed in immortalized human keratinocytes and several CC-derived radio-resistant cell lines (Chen *et al.*, 2002; Liu *et al.*, 2003), but suppressed in radiosensitive cell lines (Crawford & Piwnica-Worms, 2001; Chaudhry *et al.*, 2003).

Unfortunately, is difficult to find a clear correlation of differentially expressed genes between different microarray studies related to radiation therapy because the response is not only different in every patient, but it also depends on the dose, type, time, etc. In spite of this, other radiation-related tumor markers (Haffty & Glazer, 2003) have also been detected including cyclin D1 (CCND1), the factor vascular endothelial growth factor (VEGF) and the proliferating cell nuclear antigen (PCNA), though in isolated studies (Chen *et al.*, 2002; Chaudhry *et al.*, 2003; Liu *et al.*, 2003).

4.3.2 Chemotherapy

Similar to radiation, there are several studies but using instead chemical agents. For example, using cell lines derived from CC with and without HPV infection, the effect of anticancer substances that stop cell cycle like lovastatin has been study in a comprehensive manner (Dimitroulakos *et al.*, 2002). Other chemicals have been used like the apoptosis-inducing di-indol-methane (Carter *et al.*, 2002), catechin EGCG (found in green tea) (Ahn *et al.*, 2003), arsenic-derived (As_2O_3 and As_4O_6) (Ahn *et al.*, 2004b), and platinum-derived compounds (Gatti *et al.*, 2004) as well as the antibiotic zeocin (Hwang *et al.*, 2005). In addition, several effects exerted by chemicals that inhibit the epidermal growth factor receptor (EGFR) oncogene (Woodworth *et al.*, 2005) and phosphatidylinositol kinase (PIK3CA) (Lee *et al.*, 2006) signaling pathways had been also assessed. However, since these compounds are highly toxic, with broad action spectra, similar to those of radiotherapy, only very slight correlations of activated or deactivated genes across all these studies can be observed. For example, the expression of pro-metastatic factor JAG2 is suppressed when CC

cell lines were treated with platinum-containing compounds (Gatti *et al.*, 2004) or di-indolymethane (Carter *et al.*, 2002). Di-indolymethane (Carter *et al.*, 2002) or arsenic compounds (Ahn *et al.*, 2004b), on the other hand, suppressed the transcripts of the proliferation marker PCNA.

It has been likewise reported that the transcription factor E2F4 can be suppressed by the competitive inhibition (in the ATP binding-site) of the EGFR (Woodworth *et al.*, 2005) or simply using zeocin (Hwang *et al.*, 2005). Another gene involved in cell proliferation is CHEK1, which can be suppressed by zeocin (Hwang *et al.*, 2005) and derivatives of arsenic (Ahn *et al.*, 2004b). Lastly, the membrane marker CD83 (antigen involved in immunologic response) has also been down-regulated using arsenic compounds (Ahn *et al.*, 2004b) and EGCG (Ahn *et al.*, 2003). Despite efforts to improve the prognosis of patients through the use of diverse chemotherapy regimens, radiation and their combinations, the quality of life, generally speaking, has not been yet improved significantly (Duenas-Gonzalez *et al.*, 2003). Owed to this, the search for new tumor markers and the development of drugs specifically targeted against these molecules is an important step to control CC.

5. A systematic view on cervical cancer

Systems biology (SB) seeks to explain biological phenomena through the study of networks that emerge because of the interactions of the cellular and biochemical components of a cell or organism (Kitano, 2002). This can be achieved with the aid of bioinformatics, as it allows the integration of large amounts of information that are generated every day as well as the construction of biology-oriented mathematical models. In fact, not only transcriptional network models for the understanding of cancer have been simulated, but also the integration of microarray-derived data has been a useful tool for identifying gene modules involved in different cancer-altered pathways (Segal *et al.*, 2005). Furthermore, it has been shown that cancer alterations can be better correlated when these are compared to different organisms, suggesting that combining data obtained from both cell lines and various techniques can provide more compelling ideas to understand biological phenomena.

5.1 Systems biology and cervical cancer

All available information from the cancer transcriptome could be easily correlated if the respective studies would share a universal language e.g. MIAME (Minimal Information About a Microarray Experiment) (Quackenbush, 2004).

Most microarray reports and in particular those in CC, however, contain no standardized data. Using a database and different computational tools (Kent, 2002; Wain *et al.*, 2004; Wheeler *et al.*, 2008) to assign all genes the same nomenclature, it is nonetheless possible to assess their expression levels and correlate them in different scenarios. For example, from all the aforementioned CC microarray studies, when assessing only "on"/"off" expression, we observed genes commonly found between some studies (Table 1).

Many of the genes in Table 1 have been implicated before in CC. Nevertheless, these genes can be related to other high performance techniques, such as the identification of tumor suppressor genes among a big set of genes that increase their expression during loss of tumorigenicity in HeLa cells (Mikheev *et al.*, 2004) or the quantification of transcripts present in samples of CC (Frigessi *et al.*, 2005) or normal cervix (Perez-Plasencia *et al.*, 2005).

Up-regulated genes in cervical cancer		Down-regulated genes in cervical cancer	
Gene	*References*	*Gene*	*References*
TOP2A	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	CDKN1A	(Chang & Laimins, 2000), (Nees *et al.*, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Thierry *et al.*, 2004), (Wells *et al.*, 2003), (Kelley *et al.*, 2005)
CCNA2	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	FN1	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Toussaint-Smith *et al.*, 2004), (Kelley *et al.*, 2005), (Santin *et al.*, 2005), (Hudelist *et al.*, 2005)
CCNB1	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005), (Vazquez-Ortiz *et al.*, 2005a), (Liu *et al.*, 2003)	TRIM22	(Chang & Laimins, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Pett *et al.*, 2006), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)
CDKN2A	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Rosty *et al.*, 2005), (Santin *et al.*, 2005), (Hudelist *et al.*, 2005)	IL1RN	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006), (Santin *et al.*, 2005)
PLK1	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Pett *et al.*, 2006), (Wells *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	SPRR1A	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Alazawi *et al.*, 2002), (Wong *et al.*, 2006), (Santin *et al.*, 2005)
BIRC5	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	TNC	(Duffy *et al.*, 2003), (Garner-Hamrick *et al.*, 2004), (Pett *et al.*, 2006), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)
MCM2	(Garner-Hamrick *et al.*, 2004), (Wells *et al.*, 2003), (Wong *et al.*, 2006), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	IGFBP6	(Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Hudelist *et al.*, 2005), (Liu *et al.*, 2003)
NEK2	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	LCN2	(Chang & Laimins, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Santin *et al.*, 2005)
BUB1	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Wells *et al.*, 2003), (Rosty *et al.*, 2005)	ABCA1	(Garner-Hamrick *et al.*, 2004), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)
CCNB2	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	BNIP2	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Wong *et al.*, 2006)
CDC2	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Wells *et al.*, 2003), (Rosty *et al.*, 2005)	CSPG2	(Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)
CDC20	(Nees *et al.*, 2001), (Wells *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	DDB2	(Duffy *et al.*, 2003), (Thierry *et al.*, 2004), (Kelley *et al.*, 2005)
CKS1B	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	GSN	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Kelley *et al.*, 2005)
E2F1	(Wells *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005), (Hudelist *et al.*, 2005)	INPP5D	(Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Wells *et al.*, 2003)
FOXM1	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	IVL	(Duffy *et al.*, 2003), (Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006)
KRT18	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005)	KLK7	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Wong *et al.*, 2006)
MEST	(Duffy *et al.*, 2003), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	KRT4	(Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006)
MKI67	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Vazquez-Ortiz et al, 2005b)	KRT16	(Alazawi *et al.*, 2002), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006)
MSH6	(Garner-Hamrick *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	LAMA3	(Chang & Laimins, 2000), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)

Up-regulated genes in cervical cancer		Down-regulated genes in cervical cancer	
Gene	*References*	*Gene*	*References*
MYBL2	(Thierry *et al.*, 2004), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	SMPG	(Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Santin *et al.*, 2005)
PRIM1	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	PI3	(Duffy *et al.*, 2003), (Alazawi *et al.*, 2002), (Santin *et al.*, 2005)
RRM2	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Wong *et al.*, 2006), (Rosty *et al.*, 2005)	PPP2R5B	(Garner-Hamrick *et al.*, 2004), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)
SPARC	(Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Chen *et al.*, 2003), (Ahn *et al.*, 2004a)	SERPINB2	(Chang & Laimins, 2000), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)
TTK	(Garner-Hamrick *et al.*, 2004), (Wells *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	SPRR2B	(Duffy *et al.*, 2003), (Wong *et al.*, 2006), (Santin *et al.*, 2005)
VEGF	(Garner-Hamrick *et al.*, 2004), (Toussaint-Smith *et al.*, 2004), (Wong *et al.*, 2006), (Vazquez-Ortiz *et al.*, 2005a)	SULT2B1	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Wong *et al.*, 2006)

Table 1. Genes primarily found to be up- or down-regulated in cervical cancer across different DNA microarray platforms comparing non-pathogenic vs tumor samples and cell lines. The internationally accepted nomenclature for each gene can be found in: http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder.

Moreover, it is even possible to combine all this information with that derived of techniques of medium- (Nees *et al.*, 1998; Cheng *et al.*, 2002a; Brentani *et al.*, 2003; Ahn *et al.*, 2005; Ranamukhaarachchi *et al.*, 2005; Seo *et al.*, 2005; Sgarlato *et al.*, 2005) and low- (Helliwell, 2001; Keating *et al.*, 2001; Follen *et al.*, 2003; Gray & Herrington, 2004) performance in CC.

In addition, the to-be-integrated information can be further correlated with genes that have been (a) implied as potential markers in several metastatic solid tumors, including some of uterine origin (Ramaswamy *et al.*, 2003); (b) associated with cervical cancer and other kind of cancers whose somatic or germline mutations frequently favor the development of neoplasia (Forbes *et al.*, 2006); or (c) proposed as common tumor proliferation markers overexpressed across microarray reports in very diverse tumor tissues (Whitfield *et al.*, 2006). Last but not least, a more comprehensive systematic analysis of CC can be done by correlating gene up-regulation mediated via the transcription factors E2F (Bracken *et al.*, 2004) and TP53 (Wei *et al.*, 2006), being this integration crucial for a general understanding of the transcriptional regulation during CC development because the functions E2F and TP53 are respectively altered by the oncoproteins E7 and E6. The idea of integrating all these additional supporting studies from many sources poses great potential in the diagnosis, prevention, and treatment of cancer as has been shown in liver carcinoma (Thorgeirsson *et al.*, 2006).

5.2 Systematic model of HPV-mediated cervical carcinogenesis

The invaluable information provided by all the aforementioned microarray-based CC reports can be related to those additional supporting studies through an integrative disease model as the HPV-mediated cervix carcinogenesis develops in a complex multiple-step process (Sherman & Kurman, 1998; Klaes *et al.*, 1999; zur Hausen, 2002; Sherman, 2003; Ahn *et al.*, 2004a; Frazer, 2004; Pett *et al.*, 2006; Snijders *et al.*, 2006). It starts with the HR-HPV infection and episomes formation thereof, followed by the production of virions and/or the integration of the viral genome into the host one that can lead to precancerous and

cancerous lesions of squamous and/or glandular origin and ultimately to death. In other words, with this model (Fig. 3) it is not only possible to correlate the up/down regulation of


Fig. 3. Cervix carcinogenesis systematic model. The various nomenclatures employed in the histopathology of cervical cancer are aligned by dashed lines and extended to key cellular and molecular events that occur during the transformation of the epithelium. The solid lines indicate a direct relationship between key events. A key event is the infection of cells in the basal membrane by HR-HPVs. These can turn into episomal bodies, which will be in charge of, on one hand, producing infective virions and, on the other, integrating into the genome of epithelial cells. Upon infection, an average of 2-3 years are necessary to develop cervical intraepithelial neoplasia of low- (CIN1/2) and/or high-grade (CIN3), often characterized by the integration of the viral genome, another key event for the disease progression as this often triggers the deregulation of the oncogenes E6 and E7, mayor chromosomal alterations and cellular immortalization. The immune system plays a key role during carcinogenesis since the majority of HR-HPV infections (80%) as well as most low-grade lesions (80%) regress. Due to this and the long periods of time between viral infection and the progression to invasive disease, the infection by HR-HPVs is necessary but not sufficient for the development of cervical cancer; in addition, the inactivation of anti-oncogenes (besides pRb and p53) and activation of oncogenes are necessary to consequently provoke changes at the (epi-)genomic, transcriptomic and protemic level. *D* = Displasia; L- or HSIL = Low- or High-grade squamous intraepithelial lesion.

specific genes upon presence/absence of HR-HPVs episomes or genome integration as well as that of the oncoproteins E6 and/or E7, but also to identify specific carcinogenesis targets.

Depending on the study, however, the gene correlation has to be carefully done, for example, the processes of cell differentiation and senescence (Nees *et al.*, 2000; Wells *et al.*, 2003; Ranamukhaarachchi *et al.*, 2005) have been considered as anti-cell proliferation molecular events (Gandarillas, 2000). Similarly, an indirect correlation could be observed for gene activation mediated by LR-HPVs (Thomas *et al.*, 2001) but not HR-HPVs or E6 and E7 oncogene suppression (Wells *et al.*, 2003; Thierry *et al.*, 2004; Kelley *et al.*, 2005) by E2 (Dowhanick *et al.*, 1995) or RNA interference (Novina & Sharp, 2004). More importantly, nonetheless, as will be discussed in the coming subsections, this model allows the comparison of candidate tumor markers to data obtained from other CC studies at the genomic (Lazo, 1999; Wilting *et al.*, 2006), transcriptomic (Martin *et al.*, 2006), proteomic (Bae *et al.*, 2005; Choi *et al.*, 2005; Yim & Park, 2006) and epigenomic (Duenas-Gonzalez *et al.*, 2005; Sova *et al.*, 2006) level.

5.3 Up-regulated candidate tumor markers

Although many genes frequently activated in CC have been reported using microarrays, other techniques and analyses strongly suggest that these are tumor markers. This can be illustrated with the inhibitor of cyclin-dependent kinases (CDKs) *p16^INK4a* or *CDKN2A*, which is involved in cell cycle and has been categorized as a tumor marker in the development of CC (Keating *et al.*, 2001). Overexpression of *p16^INK4a* at both the transcript and protein level can be detected in samples of cervical dysplasia, squamous and glandular HR-HPV positive and negative lesions when compared with normal cervix by low-throughput techniques (Martin *et al.*, 2006). As summarized in Table 2, *p16^INK4a* up-regulation has been also found using medium- (Brentani *et al.*, 2003) and high-performance methods when the oncoprotein E7 is expressed in cell lines *in vitro* (Nees *et al.*, 2001; Garner-Hamrick *et al.*, 2004), in patient samples *in vivo* (Rosty *et al.*, 2005) and when comparing tumors vs normal tissue (Hudelist *et al.*, 2005; Rosty *et al.*, 2005; Santin *et al.*, 2005; Wong *et al.*, 2006).

Interestingly, *p16^INK4a* is one of the genes that can display somatic mutations in CC; an abnormal status that has been linked to the development of cervical squamous cell cancer (SCC) (Forbes *et al.*, 2006). Dozens of references in the literature demonstrate that the overexpression of *p16^INK4a* is useful as a CC tumor marker; however, using patient samples, others have determined transcript inactivation due to strong hypermethylation on its promoter region (Duenas-Gonzalez *et al.*, 2005). Although these findings are contradictory at first glance, some subpopulations of dysplastic cervical cells can also display epigenetic silencing of *p16^INK4a* and associated low protein levels (Nuovo *et al.*, 1999). This suggests that the expression of *p16^INK4a* is inhibited in some cells within the tumor, whereas its overexpression can be abundant in other cells, most probably expressing the oncoprotein E7. In spite of this, the detection of *p16^INK4a* is very useful in the cytological diagnosis of CC and, furthermore, recent evidence suggests that the determination of the *p16^INK4a* protein may be even more useful than the already-established HR-HPVs detection in the cytological diagnosis (Nieh *et al.*, 2005).

Another important up-regulated gene is "survivin" or *BIRC5* (Table 2). Although surviving expression is undetectable in normal adult tissues, its expression can be detected normally

Biological Process	Gene (Locus)[A]	References												
		Throughput[B]			Marker[C]			TF[D]		Analysis[E]			
		High-	Medium-	Low-	Metastasis	Cancer	Proliferation	E2F	TP53	Genome	Transcriptome	Proteome	Epigenome
Cell Cycle	MKI67 (Ag Ki-67) (10q25-ter)	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Vazquez-Ortiz *et al.*, 2005b)	(Brentani *et al.*, 2003)	(Follen *et al.*, 2003)	-	-	(Whitfield *et al.*, 2006)	(Bracken *et al.*, 2004)	-	-	-	-	-
	CDKN2A (p16INK4a) (9p21)	(Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Rosty *et al.*, 2005), (Santin *et al.*, 2005), (Hudelist *et al.*, 2005)	(Brentani *et al.*, 2003)	(Keating *et al.*, 2001)	-	(Forbes *et al.*, 2006)	-	-	-	(Martin *et al.*, 2006)	-	Gonzalez *et al.*,
	CCNB1 (5q12)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005), (Vazquez-Ortiz *et al.*, 2005a), (Liu *et al.*, 2003)	(Brentani *et al.*, 2003) (Sgarlato *et al.*, 2005) (Cheng *et al.*, 2002a)	-	-	-	(Whitfield *et al.*, 2006)	-	(Wilting *et al.*, 2006)	-	-	-
	PLK1 (16p12.1)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Pett *et al.*, 2006), (Wells *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)		-	-		-	-	-	-	-	-
	CCNA2 (4q25-31)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)		-	-	-	-	-	-	-	-	-
	MSH6 (2p16)	(Garner-Hamrick *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Ranamukhaar achchi *et al.*, 2005)	-	(Forbes *et al.*, 2006)		(Bracken *et al.*, 2004)	*al.*, 2005	-	-	-	-
	MAD2L1 (4q27)	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Wells *et al.*, 2003), (Rosty *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	(Whitfield *et al.*, 2006)	(Bracken *et al.*, 2004)	-	-	-	-	-
	CKS1B (1q21.2)	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	-		-			(Wilting *et al.*, 2006)	-	-	-
	SMC4L1 (3q26.1)	(Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003) (Ranamukhaar achchi *et al.*, 2005)	-	-	-	-			-	-	-
	ZWINT (10q21-22)	(Thierry *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003) (Sgarlato *et al.*, 2005)	-	-	-	-	-	-	-	-	-	-
Apoptosis	BIRC5 (17q25)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	(Whitfield *et al.*, 2006)	-	-	-	-	-	-

	MYBL2 (20q13.1)	(Thierry *et al.*, 2004), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003) (Sgarlato *et al.*, 2005)	-	-	-	-	(Bracken *et al.*, 2004)	(Wilting *et al.*, 2006)	(Martin *et al.*, 2006)	-	-
	LMNB1 (5q23.3-31)	(Garner-Hamrick *et al.*, 2004), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	-	(Kamaswamy *et al.*, 2003)	-	-	-	-	-	-	-	-
DNA replication	TOP2A (17q21-22)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	(Whitfield *et al.*, 2006)	(Bracken *et al.*, 2004)	-	(Martin *et al.*, 2006)	-	-
	MCM2 (3q21)	(Garner-Hamrick *et al.*, 2004), (Wells *et al.*, 2003), (Wong *et al.*, 2006), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003) (Sgarlato *et al.*, 2005)	-	-	-	(Whitfield *et al.*, 2006)	(Bracken *et al.*, 2004)	(Wilting *et al.*, 2006)	(Martin *et al.*, 2006)	-	-
	MCM4 (8q11.2)	(Ruutu *et al.*, 2002), (Chen *et al.*, 2003), (Rosty *et al.*, 2005), (Santin *et al.*, 2005)	-	-	-	-	(Whitfield *et al.*, 2006)	-	(Wilting *et al.*, 2006)	-	-	-
Morphogenesis	KRT19 (17q21-23)	(Garner-Hamrick *et al.*, 2004), (Alazawi *et al.*, 2002), (Wong *et al.*, 2006), 113	(Brentani *et al.*, 2003)	-	-	-	-	-	-	-	*al.,*	-
	KRT18 (12q13)	(Garner-Hamrick *et al.*, 2004), (Thierry *et al.*, 2004), (Sopov *et al.*, 2004), (Rosty *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	-	-	-	-	-	-
Angiogenesis	VEGF (6p21-12)	(Garner-Hamrick *et al.*, 2004), (Toussaint-Smith *et al.*, 2004), (Wong *et al.*, 2006), (Vazquez-Ortiz *et al.*, 2005a)	-	(Helliwell, 2001)	-	-	-	-	-	(Martin *et al.*, 2006)	-	-
	VEGFC (4q33-34)	(Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Pett *et al.*, 2006)	-	-	-	-	-	-	-	-	-	-

Table 2. Genes frequently reported as up-regulated in cervical cancer (CC). A) For each biological process, genes are listed in descending order by the mayor number of reports related to CC e.g. the gene MKI67 has been reported at least 190 times in CC. Genes in bold have been used as therapeutic targets in cancer, whereas genes in italics are not so known in CC. The chromosomal localization of the gene is shown in brackets. B) Techniques of high-throughput are DNA microarrays; medium- DD, RDA and ESTs; and low- are tumor markers previously defined in CC. C) Genes proposed as metastasis markers (in solid tumors), tumoral cancer markers (due to frequent mutations) and proliferation markers (large number of cancers). D) Transcription factor (TF) that might regulate the corresponding gene. E) The analysis of the genome refers to the most common chromosomal gains in CC (1q, 3q, 5p, 8q, 20q and Xq); transcriptome to the importance of genes in CC; proteome to overexpressed proteins in CC and; epigenome to genes whose promoter has been found methylated in samples derived from CC. For gene nomenclature see Table 1.

in embryogenesis and abnormally in cancer (mainly inhibiting apoptosis). Due to this, survivin has been generally proposed as a proliferation tumor marker in cancer (Whitfield *et al.*, 2006)

and particularly in CC (Branca *et al.*, 2005), opening promising therapeutic strategies (Altieri, 2006). Other emergent useful target genes are the members 2 and 4 from the "minichromosome maintenance deficient" complex or *MCM* found, genes primary involved in DNA replication that have been considered useful for cancer diagnosis and therapy (Rosty et al., 2005; Santin et al., 2005). Similarly, other up-regulated genes that could be specifically targeted are the 2α topoisomerase or *TOP2A* (Whitfield *et al.*, 2006), cyclin B1 or *CCNB1* (Yuan *et al.*, 2004), the kinase 1 polo type or *PLK1* (Strebhardt & Ullrich, 2006) and keratin 19 or *KRT19* (Chang *et al.*, 2005). The transcripts of the latter gene have been abundantly estimated not only in CC-derived samples (Frigessi *et al.*, 2005), but also determined as overexpressed at both the messenger (Alazawi *et al.*, 2002; Brentani *et al.*, 2003; Garner-Hamrick *et al.*, 2004; Wong *et al.*, 2006), and protein (Bae *et al.*, 2005) level in cervical neoplasia compared to normal tissue. As *KRT19*, a protein part of the intermediate filaments of epithelial cells, *KRT18* (Table 2) could likewise play an important role in the molecular diagnosis of cancer.

It should be noted that several genes reported in Table 2 only have been linked to CC using high and average performance techniques, such as the gene involved in the structural maintenance of chromosomes "*SMC4L1*". As far as we known, a single report correlated the expression levels of this gene to esophageal squamous cancer (Yen *et al.*, 2005), but a genomic analysis showed that chromosomal gains in the region 3q12.1- 28 (where *SMC4L1* lies) are most common in SCC (Wilting *et al.*, 2006). This gene might be activated by E2F (Bracken *et al.*, 2004), but it is desirable to check the expression levels of SMC4L1 with low-yield techniques to determine its relevance in CC as well as for potential metastatic markers like LMNB1 or proliferation ones like MAD2L1 gene (Table 2).

5.4 Down-regulated candidate tumor markers

Using microarrays and other techniques it has been possible to find genes frequently down-regulated in CC, suggesting that these may play a role as tumor markers e.g. the tumor suppressor gene *p21^{WAF1/CIP1}* or *CDKN1A*, which regulates the cell cycle via CDKs inhibition, senescence as well as TP53-dependent and -independent apoptosis (Table 3). Upon degradation or inactivation of the nuclear phosphoprotein TP53 by E6 or PLK1, respectively, the transcription of *p21^{WAF1/CIP1}* is reduced as observed in several types of cancer (Gartel & Radhakrishnan, 2005) and particularly in CC samples using DNA microarrays (Chang & Laimins, 2000; Nees *et al.*, 2000; Nees *et al.*, 2001; Duffy *et al.*, 2003; Wells *et al.*, 2003; Thierry *et al.*, 2004; Kelley *et al.*, 2005). In addition, it has been suggested that low *p21^{WAF1/CIP1}* expression correlates with poor prognosis in cervical adenocarcinoma (AC) (Lu *et al.*, 1998). Moreover, in samples derived from CC it has been observed a decrease in cell growth and induction of *p21^{WAF1/CIP1}* by platinum-based chemotherapy (Gatti *et al.*, 2004) as well as radioimmunotherapy directed against KRT19 (Chang *et al.*, 2005).

Other down-regulated genes in CC include the gene desmoglein 1 or *DSG1*, which encodes a protein involved in the homeostasis of cell-cell epithelial junctions and belongs to the family of "cadherins", proteins whose expression decreases as it progresses in many kinds of cancers, such as cervical cancer (de Boer *et al.*, 1999). It has been determined that the expression of *DSG1* increases in presence of LR-HPVs episomal bodies in human keratinocytes, but its expression levels highly decrease when HR-HPV episomes are present in cell lines and SCC samples. Moreover, DSG1 importantly lies in an area that often presents chromosomal losses during CC (Table 3) and has been assigned as a pro-apoptotic factor mediated by the caspase 3 in keratinocytes (Dusek *et al.*, 2006).

Biological Process	Gene (Locus)[A]	References						
		Throughput[B]			Marker[C]		TF[D]	Analysis[E]
		High-	*Medium-*	*Low-*	*Metastasis*	*Cancer*	*TP53*	*Genome*
Cell Cycle	CDKN1A (p21[WAF1/CIP1]) (6p21.1)	(Chang & Laimins, 2000), (Nees *et al.*, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Thierry *et al.*, 2004), (Wells *et al.*, 2003), (Kelley *et al.*, 2005)	-	-	-	-	(Nees *et al.*, 2000)	-
Cell Adhesion	FN1 (2q34-36)	(Nees *et al.*, 2000), (Nees *et al.*, 2001), (Toussaint-Smith *et al.*, 2004), (Kelley *et al.*, 2005), (Santin *et al.*, 2005), (Hudelist *et al.*, 2005)	-	-	-	-	-	(Wilting *et al.*, 2006)
	DSG1 (18q12.1)	(Chang & Laimins, 2000), (Thomas *et al.*, 2001), (Wong *et al.*, 2006)	-	-	-	-	-	(Wilting *et al.*, 2006)
	CSPG2 (5q12-14)	(Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	-	(Wilting *et al.*, 2006)
Apoptosis	SERPINB2 (18q21.3)	(Chang & Laimins, 2000), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	-	(Lazo, 1999)
	BNIP2 (10q26.3)	(Nees *et al.*, 2001), (Thierry *et al.*, 2004), (Wong *et al.*, 2006)	-	-	-	-	-	-
Immune Response	IL1RN (2q14.2)	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006), (Santin *et al.*, 2005)	-	-	-	-	-	(Wilting *et al.*, 2006)
	TRIM22 (11p15)	(Chang & Laimins, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Pett *et al.*, 2006), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)	-	-	-	-	(Nees *et al.*, 2000)	-
Epidermal Development	KLK7 (19q13.41)	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Wong *et al.*, 2006)	-	-	-	-	-	(Lazo, 1999)
	KRT4 (12p12-11)	(Duffy *et al.*, 2003), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006)	(Brentani *et al.*, 2003)	(Contag *et al.*, 2004)	-	-	-	-
	KRT16 (17q12–21)	(Alazawi *et al.*, 2002), (Ruutu *et al.*, 2002), (Wong *et al.*, 2006)	(Brentani *et al.*, 2003)	-	-	-	-	-
	LAMA3 (18q11.2)	(Chang & Laimins, 2000), (Kelley *et al.*, 2005), (Santin *et al.*, 2005)	-	-	-	-	-	(Wilting *et al.*, 2006)
	SPRR3 (1q21-22)	(Wong *et al.*, 2006), (Santin *et al.*, 2005), (Perez-Plasencia *et al.*, 2005)	-	-	-	-	-	-

	Gene							
	SPRR1A (1q21-22)	(Chang & Laimins, 2000), (Duffy *et al.*, 2003), (Alazawi *et al.*, 2002), (Wong *et al.*, 2006), (Santin *et al.*, 2005)	-	-	-	-	-	-
Signal Transduction	*INPP5D* (2q36-37)	(Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Wells *et al.*, 2003)	-	-	-	-	-	(Wilting *et al.*, 2006)
	IGFBP6 (12q13)	(Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Hudelist *et al.*, 2005), (Liu *et al.*, 2003)	-	-	-	-	-	-
	PPP2R5B (11q12)	(Garner-Hamrick *et al.*, 2004), (Ruutu *et al.*, 2002), (Santin *et al.*, 2005)	-	-	-	-	-	(Wilting *et al.*, 2006)
DNA Repair	MPG (16p13.3)	(Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006), (Santin *et al.*, 2005)	(Seo *et al.*, 2005)	-	-	-	-	-
	DDB2 (11p12-11)	(Duffy *et al.*, 2003), (Thierry *et al.*, 2004), (Kelley *et al.*, 2005)	-	-	-	(Forbes *et al.*, 2006)	(Nees *et al.*, 2000)	-
DNA Transcr iption	*RUNX1* (21q22.3)	(Garner-Hamrick *et al.*, 2004), (Wong *et al.*, 2006)	-	-	(Ramaswamy *et al.*, 2003)	(Forbes *et al.*, 2006)	-	-
Cellular Transport	*LCN2* (9q34)	(Chang & Laimins, 2000), (Nees *et al.*, 2001), (Duffy *et al.*, 2003), (Santin *et al.*, 2005)	(Brentani *et al.*, 2003)	-	-	-	-	-

Table 3. Genes frequently reported as down-regulated in cervical cancer (CC). A) For each biological process, genes are listed in descending order by the mayor number of reports related to CC e.g. the gene *CDKN1A* has been reported at least 70 times in CC. Genes in bold represent increased expression levels upon different schemes of radio and/or chemotherapy, whereas genes in *italics* are not so known in CC. The chromosomal localization of the gene is shown in brackets. B) Techniques of high-throughput are mainly DNA microarrays; medium- DD, and ESTs; and low- are tumor markers previously defined in CC. C) Genes proposed as metastasis markers (in solid tumors) and tumoral cancer markers (due to frequent mutations). D) Transcription factor (TF) that might regulate the corresponding gene. E) The analysis of the genome refers to the most common chromosomal alterations in CC (2q, 3p, 4p, 5p, 5q, 6p, 6q, 11q, 13q, 18q and 19q). For gene nomenclature see Table 1.

Another gene that could be of interest in CC is *SERPINB2*. The gene product is an inhibitor of the serine-type proteases like the plasminogen activator (also known as *PLAU*). On one hand, *SERPINB2* suppression has been determined using both microarrays as well as genomic studies in CC (Table 3); but on the other, its expression in HeLa cells can stabilize the expression levels of the Rb protein and suppress the oncoproteins E6 and E7 of HPV18 (Darnell *et al.*, 2005). This suggests that low levels of *SERPINB2* promote CC development, being this a potentially good molecular marker.

Of genes not known in CC there are several examples, being the gene *TRIM22* or "tripartite motif-containing 22", which has been found down-regulated in at least 6

microarray studies (Table 3). *TRIM22* belongs to a conserved family of antiviral proteins, where the member 22 has been implicated in inhibiting the replication of the human immunodeficiency virus 1 (HIV1) (Nisole *et al.*, 2005). This suggests that TRIM22 may be relevant in the immune response HR-HPVs and that these viruses may be responsible for its inhibition.

Table 3 also lists genes from the epidermal differentiation complex (EDC, located in the band 21 of the long arm of chromosome 1), for instance, using SAGE, abundant transcripts of *SPRR3* have been found in normal cervical tissue, but a low *SPRR3* expression has been determined in tumor tissue using microarrays (Table 3). This suggests that *SPRR3* and perhaps *SPRR1A,* which also belongs to the EDC, may be useful tumor markers in CC. Last, other suppressed genes in CC are *IGFBP6* and *RUNX1* (Table 3). While the first one is responsible for inactivating a potent growth factor similar to insulin (IGF2), a gene in turn required by IGFBP6 to reduce metastatic characteristics in tumors from different origin (Bach, 2005), the second gene belongs to a family of transcription factors that can inhibit angiogenesis (Sakakura *et al.*, 2005).

5.5 Candidate tumor markers in cervical cancer subtypes

Although HPV-16-infections are more frequently detected than HPV-18 ones in squamous cell carcinoma (SCC), the latter ones are more often associated to adenocarcinoma of the cervix (AC), whose incidence is growing at the same time as SCC incidence. Interestingly, several genes with a clinically usefulness for the molecular differentiation between the two major histological subtypes of CC have been found using DNA microarrays (Table 4). The genes *TACSTD1* and *CEACAM5,* which encode transmembrane proteins that transmit signals for development, motility and cell growth, for example, were found to be upregulated in AC compared to SCC (Chao *et al.*, 2006).

Up-regulated genes in squamous cell carcinoma		Up-regulated genes in adenocarcinoma	
Gene	*Reference*	*Gene*	*Reference*
CRABP2	(Chao *et al.*, 2006)	BIRC3	(Fujimoto *et al.*, 2004)
NDRG1	(Chao *et al.*, 2006)	CEACAM1	(Fujimoto *et al.*, 2004)
CDH13	(Fujimoto *et al.*, 2004)	CEACAM5-7	(Chao *et al.*, 2006)
KRT13	(Chao *et al.*, 2006)	FOLR1	(Fujimoto *et al.*, 2004)
KRT15	(Chao *et al.*, 2006)	MSLN	(Chao *et al.*, 2006)
PTHLH	(Fujimoto *et al.*, 2004)	S100P	(Chao *et al.*, 2006)
S100A9	(Chao *et al.*, 2006)	TACSTD1	(Chao *et al.*, 2006)
SPRR1B	(Chao *et al.*, 2006)	TSPAN3	(Chao *et al.*, 2006)

Table 4. Genes with a possible clinical utility for the molecular differentiation between squamous cell carcinoma (SCC) and adenocarcinoma (AC) in cervical cancer. The internationally accepted nomenclature for each gene can be found in: http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder.

Furthermore, high levels of the corresponding proteins served by themselves as poor prognostic factors in patients with AC compared with SCC (Chao *et al.*, 2006). Other genes for potential use as markers in CC that have been found with microarrays are:

1. *CRABP2* (belongs to the EDC and encodes the retinoic acid binding protein 2) has been identified as up-regulated in SSC compared to normal tissue (Shim *et al.*, 1998; Seo *et al.*, 2005) and AC (Chao *et al.*, 2006).
2. *NDRG1* (N-myc Downstream Regulated Gene 1) is involved in cell growth and differentiation and was found overexpressed in SCC compared to AC (Chao *et al.*, 2006) and normal cervical tissue (Sgarlato *et al.*, 2005).
3. Other members of the "Carcinoembryonic antigen-related cell adhesion molecule" family such as the *CEACAM-1*, *-5*, *-6*, and *-7*, are shown as up-regulated in AC compared to SCC (Fujimoto *et al.*, 2004; Chao *et al.*, 2006).
4. *MSLN* or mesothelin encodes a membrane glycoprotein involved in cell adhesion whose transcripts are detectable in normal tissue but abundant in tumors of glandular origin or HeLa cells. In CC, *MSLN* is overexpressed in AC compared to SCC (Chao *et al.*, 2006) and in HPV-18-derived samples of SCC/AC compared to normal tissue (Rosty *et al.*, 2005). It is worth noting that *MSLN* is a therapeutic target in various malignancies (Hassan *et al.*, 2004).
5. Finally, high expression levels of *FOLR1* (folate receptor) have been associated with an AC phenotype (Fujimoto *et al.*, 2004) and tumorigenicity in cell lines derived from AC (Mikheev *et al.*, 2004). However, further studies are required to demonstrate the relevance of this receptor in both AC and SCC because it is known that via FOLR1 and folic acid, its ligand, some drugs can be bound and directed into over-expressing high levels of *FOLR1,* as suggested in several types of cancer (Kelemen, 2006).

The aforementioned "tumoral markers" could be potentially important for the diagnosis, prevention, and treatment of CC because these were identified using cell lines from various sources as well as samples of SCC and/or AC for comparative studies with normal tissues. Last but not least, a recent and interesting CC review not only proposed a similar systematic model of HPV infection highlighting the current debate on the viral status as hallmark of disease progression (episomal vs integrated forms where HPV-18 genome integration seems to prevail in women with advance disease in contrast to HPV-16), but also provided overlapping and additional tumor markers at some of those analyzed herein (Woodman *et al.*, 2007). Along these lines, it would be worth saying that cancer, including its hundred subtypes, is such a complex phenomenon (Vogelstein & Kinzler, 2004), which should be rather seen as an average of key molecular events displaying often specific hallmarks (Hanahan & Weinberg, 2000) of disease progression.

6. Conclusions

Thanks to the comparison of the cervix in normal and abnormal conditions via transcriptomics in general and particularly using DNA microarrays, it is possible to identify known and unknown clinically relevant genes for the disease progression. The next goal is to identify and validate specific tumor markers for profiling histo- and pathological subtypes. This will allow not only a molecular subclassification and more understanding of CC, but also choosing the right treatment for each patient according to its gene expression signature if there is prior knowledge about the most likely response

she would have. This is the only way to fully understand more about this complex disease.

The intention of this manuscript is to provide the reader a broad view of the transcriptome, an area that is developing rapidly, especially in cancer. It is worthwhile reemphasize that the transcriptome also consists of non-coding RNAs regulating the transcription of many genes and likewise acting as oncogenes or tumor suppressor genes. With such complexity, the best tackling to cancer will rely on predictive hypothesis, so it is important to take into account systems biology, which will allow us to better understand transcriptional networks and identify specific therapy targets for a tailored therapy.

Although there are improved programs for the early diagnosis of CC as well as very effective prophylactic vaccines against HR-HPVs, the high mortality rates triggered by CC will not diminish soon, not even in the medium-term after optimizing CC monitoring programs and broadly executing vaccination schemes. An alternative for CC patients is therefore to look at those tumor markers that could aid in the stratification of the disease and therapy. Unfortunately, genomics and all its derivatives are exacerbating global inequalities in terms of scientific research and health between developed and developing countries since the first cause of death of women in the former countries is breast cancer whereas in the latter ones CC kills every 2 hours, on average, a Mexican woman in productive age.

7. Acknowledgments

8. References

Acevedo Rocha CG, Alvarez E, Zafra de la Rosa G, Alvarez Navarro M & Gariglio P (2007) [Cervical cancer and DNA microarrays: tumour marker identification]. *Ginecologia y Obstetricia de Mexico* 75, 205-213.

Achary MP, Jaggernauth W, Gross E, Alfieri A, Klinger HP & Vikram B (2000) Cell lines from the same cervical carcinoma but with different radiosensitivities exhibit different cDNA microarray patterns of gene expression. *Cytogenetics and cell genetics* 91, 39-43.

Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, Xiao H, Merril CR, Wu A, Olde B, Moreno RF & et al. (1991) Complementary DNA sequencing: expressed sequence tags and human genome project. *Science* 252, 1651-1656.

Ahn WS, Bae SM, Lee JM, Namkoong SE, Han SJ, Cho YL, Nam GH, Seo JS, Kim CK & Kim YW (2004a) Searching for pathogenic gene functions to cervical cancer. *Gynecologic oncology* 93, 41-48.

Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim CK, Seo JS & Sin JI (2004b) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and gene expression profiles by cDNA microarray analysis in SiHa cells. *Oncology reports* 12, 573-580.

Ahn WS, Huh SW, Bae SM, Lee IP, Lee JM, Namkoong SE, Kim CK & Sin JI (2003) A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell

line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. *DNA and cell biology* 22, 217-224.

Ahn WS, Seo MJ, Bae SM, Lee JM, Namkoong SE, Kim CK & Kim YW (2005) Cellular process classification of human papillomavirus-16-positive SiHa cervical carcinoma cell using Gene Ontology. *International journal of gynecological cancer: official journal of the International Gynecological Cancer Society* 15, 94-106.

Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA & Coleman N (2002) Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. *Cancer research* 62, 6959-6965.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO & Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* 403, 503-511.

Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. *Molecular cancer therapeutics* 5, 478-482.

Alwine JC, Kemp DJ & Stark GR (1977) Method for detection of specific RNAs in agarose gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA probes. *Proceedings of the National Academy of Sciences of the United States of America* 74, 5350-5354.

Bach LA (2005) IGFBP-6 five years on; not so 'forgotten'? *Growth hormone & IGF research* 15, 185-192.

Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK, Han BD, Lee YJ, Chun HJ & Ahn WS (2005) Two-dimensional gel analysis of protein expression profile in squamous cervical cancer patients. *Gynecologic oncology* 99, 26-35.

Bartlett JM (2002) Approaches to the analysis of gene expression using mRNA: a technical overview. *Molecular biotechnology* 21, 149-160.

Berk AJ & Sharp PA (1977) Sizing and mapping of early adenovirus mRNAs by gel electrophoresis of S1 endonuclease-digested hybrids. *Cell* 12, 721-732.

Bracken AP, Ciro M, Cocito A & Helin K (2004) E2F target genes: unraveling the biology. *Trends in Biochemical Sciences* 29, 409-417.

Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjanen S, Bonifacio D, Accardi L, Zanconati F & Syrjanen K (2005) Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. *American journal of clinical pathology* 124, 113-121.

Brenner S, Johnson M, Bridgham J, Golda G, Lloyd DH, Johnson D, Luo SJ, McCurdy S, Foy M, Ewan M, Roth R, George D, Eletr S, Albrecht G, Vermaas E, Williams SR, Moon K, Burcham T, Pallas M, DuBridge RB, Kirchner J, Fearon K, Mao J & Corcoran K (2000) Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. *Nature Biotechnology* 18, 630-634.

Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Jr., Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, Ojopi EP, Osorio EC, Reis EM, Riggins GJ, Simpson AJ, de Souza S, Stevenson BJ, Strausberg RL, Tajara EH, Verjovski-Almeida S, Acencio ML, Bengtson MH,

Bettoni F, Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho Andrade LE, Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estecio MR, Sa Ferreira K, Furnari FB, Faria M, Jr., Galante PA, Guimaraes GS, Holanda AJ, Kimura ET, Leerkes MR, Lu X, Maciel RM, Martins EA, Massirer KB, Melo AS, Mestriner CA, Miracca EC, Miranda LL, Nobrega FG, Oliveira PS, Paquola AC, Pandolfi JR, Campos Pardini MI, Passetti F, Quackenbush J, Schnabel B, Sogayar MC, Souza JE, Valentini SR, Zaiats AC, Amaral EJ, Arnaldi LA, de Araujo AG, de Bessa SA, Bicknell DC, Ribeiro de Camaro ME, Carraro DM, Carrer H, Carvalho AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID, Pereira da Silva N, Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ, Ayres Ferreira C, Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR, Goldman GH, Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE, Leite LC, Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK, Montagnini A, Mourao Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ, Otsuka AY, Ruas de Melo AI, Paco-Larson ML, Guimaraes Pereira G, Pesquero JB, Pessoa JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG, Rossi BM, Rusticci M, Guerra de Sa R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares FA, Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE, Zago MA & Zalcberg H (2003) The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. *Proceedings of the National Academy of Sciences of the United States of America* 100, 13418-13423.

Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, Pronk A, Floore AN, Glas AM, Van't Veer LJ & van de Vijver MJ (2009) Validation of 70-gene prognosis signature in node-negative breast cancer. *Breast cancer research and treatment* 117, 483-495.

Bustamante C, Cheng W & Mejia YX (2011) Revisiting the central dogma one molecule at a time. *Cell* 144, 480-497.

Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *Journal of molecular endocrinology* 25, 169-193.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers E, Sotiriou C, Cardoso F & Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. *Journal of the National Cancer Institute* 98, 1183-1192.

Carter TH, Liu K, Ralph W, Jr., Chen D, Qi M, Fan S, Yuan F, Rosen EM & Auborn KJ (2002) Diindolylmethane alters gene expression in human keratinocytes in vitro. *The Journal of nutrition* 132, 3314-3324.

Chang CH, Tsai LC, Chen ST, Yuan CC, Hung MW, Hsieh BT, Chao PL, Tsai TH & Lee TW (2005) Radioimmunotherapy and apoptotic induction on CK19-overexpressing human cervical carcinoma cells with Re-188-mAbCx-99. *Anticancer research* 25, 2719-2728.

Chang YE & Laimins LA (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. *Journal of virology* 74, 4174-4182.

Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, Wei ML & Lai CH (2006) Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression. *International journal of cancer* 119, 91-98.

Chaudhry MA, Chodosh LA, McKenna WG & Muschel RJ (2003) Gene expression profile of human cells irradiated in G1 and G2 phases of cell cycle. *Cancer letters* 195, 221-233.

Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY & Li JJ (2002) Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. *Cancer research* 62, 1213-1221.

Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, Bryant B, Yang D, Meyer R, Cronin F, Gostout BS, Smith-McCune K & Schlegel R (2003) Identification of cervical cancer markers by cDNA and tissue microarrays. *Cancer research* 63, 1927-1935.

Cheng Q, Lau WM, Chew SH, Ho TH, Tay SK & Hui KM (2002a) Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. *British journal of cancer* 86, 274-281.

Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH & Hui KM (2002b) Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. *International journal of cancer* 98, 419-426.

Chin KV, Alabanza L, Fujii K, Kudoh K, Kita T, Kikuchi Y, Selvanayagam ZE, Wong YF, Lin Y & Shih WC (2005) Application of expression genomics for predicting treatment response in cancer. *Annals of the New York Academy of Sciences* 1058, 186-195.

Choi YP, Kang S, Hong S, Xie X & Cho NH (2005) Proteomic analysis of progressive factors in uterine cervical cancer. *Proteomics* 5, 1481-1493.

Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD & Bae DS (2005) Increased expression of ICAM-3 is associated with radiation resistance in cervical cancer. *International journal of cancer* 117, 194-201.

Ciro M, Bracken AP & Helin K (2003) Profiling cancer. *Current opinion in cell biology* 15, 213-220.

Clarke PA, te Poele R & Workman P (2004) Gene expression microarray technologies in the development of new therapeutic agents. *European journal of cancer* 40, 2560-2591.

Collins FS, Green ED, Guttmacher AE & Guyer MS (2003) A vision for the future of genomics research. *Nature* 422, 835-847.

Contag SA, Gostout BS, Clayton AC, Dixon MH, McGovern RM & Calhoun ES (2004) Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. *Gynecologic oncology* 95, 610-617.

Costa FF (2010) Non-coding RNAs: Meet thy masters. *Bioessays* 32, 599-608.

Coulton G (2004) Are histochemistry and cytochemistry 'Omics'? *Journal of molecular histology* 35, 603-613.

Couzin J (2003) Medicine. Tracing the steps of metastasis, cancer's menacing ballet. *Science* 299, 1002-1006.

Crawford DF & Piwnica-Worms H (2001) The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. *The Journal of biological chemistry* 276, 37166-37177.

Crick F (1970) Central dogma of molecular biology. *Nature* 227, 561-563.

Darnell GA, Antalis TM, Rose BR & Suhrbier A (2005) Silencing of integrated human papillomavirus type 18 oncogene transcription in cells expressing SerpinB2. *Journal of virology* 79, 4246-4256.

de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ & Litvinov SV (1999) Changing roles of cadherins and catenins during progression of squamous intraepithelial lesions in the uterine cervix. *The American journal of pathology* 155, 505-515.

Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W, Jr., Zago MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baia GS, Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, O'Hare MJ, Soares F, Brentani RR, Reis LF, de Souza SJ & Simpson AJ (2000) Shotgun sequencing of the human transcriptome with ORF expressed sequence tags. *Proceedings of the National Academy of Sciences of the United States of America* 97, 3491-3496.

Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ & Kamel-Reid S (2002) Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. *Neoplasia* 4, 337-346.

Domazet B, Maclennan GT, Lopez-Beltran A, Montironi R & Cheng L (2008) Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. *International journal of clinical and experimental pathology* 1, 475-488.

Dowhanick JJ, McBride AA & Howley PM (1995) Suppression of cellular proliferation by the papillomavirus E2 protein. *Journal of virology* 69, 7791-7799.

Duenas-Gonzalez A, Cetina L, Mariscal I & de la Garza J (2003) Modern management of locally advanced cervical carcinoma. *Cancer treatment reviews* 29, 389-399.

Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C & Cervera E (2005) Epigenetics of cervical cancer. An overview and therapeutic perspectives. *Molecular cancer* 4, 38.

Duffy CL, Phillips SL & Klingelhutz AJ (2003) Microarray analysis identifies differentiation-associated genes regulated by human papillomavirus type 16 E6. *Virology* 314, 196-205.

Dusek RL, Getsios S, Chen F, Park JK, Amargo EV, Cryns VL & Green KJ (2006) The differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 target that regulates apoptosis in keratinocytes. *The Journal of biological chemistry* 281, 3614-3624.

Follen M, Meyskens FL, Jr., Alvarez RD, Walker JL, Bell MC, Storthz KA, Sastry J, Roy K, Richards-Kortum R & Cornelison TL (2003) Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. *Cancer* 98, 2044-2051.

Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA & Stratton MR (2006) Cosmic 2005. *British journal of cancer* 94, 318-322.

Forrest ARR, Taylor DF, Crowe ML, Chalk AM, Waddell NJ, Kolle G, Faulkner GJ, Rimantas K, Katayama S, Wells C, Kai C, Kawai J, Carninci P, Hayashizaki Y & Grimmond SM (2006) Genome-wide review of transcriptional complexity in mouse protein kinases and phosphatases. *Genome Biology* 7, R5.

Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. *Nature Reviews Immunology* 4, 46-54.

Frigessi A, van de Wiel MA, Holden M, Svendsrud DH, Glad IK & Lyng H (2005) Genome-wide estimation of transcript concentrations from spotted cDNA microarray data. *Nucleic Acids Research* 33, e143.

Frith MC, Pheasant M & Mattick JS (2005) The amazing complexity of the human transcriptome. *European journal of human genetics : EJHG* 13, 894-897.

Fujimoto T, Nishikawa A, Iwasaki M, Akutagawa N, Teramoto M & Kudo R (2004) Gene expression profiling in two morphologically different uterine cervical carcinoma cell lines derived from a single donor using a human cancer cDNA array. *Gynecologic oncology* 93, 446-453.

Fuller AP, Palmer-Toy D, Erlander MG & Sgroi DC (2003) Laser capture microdissection and advanced molecular analysis of human breast cancer. *Journal of mammary gland biology and neoplasia* 8, 335-345.

Gandarillas A (2000) Epidermal differentiation, apoptosis, and senescence: common pathways? *Experimental gerontology* 35, 53-62.

Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR & Fisher C (2004) Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. *Journal of virology* 78, 9041-9050.

Gartel AL & Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. *Cancer research* 65, 3980-3985.

Gatherer D (2010) So what do we really mean when we say that systems biology is holistic? *BMC systems biology* 4, 22.

Gatti L, Beretta GL, Carenini N, Corna E, Zunino F & Perego P (2004) Gene expression profiles in the cellular response to a multinuclear platinum complex. *Cell Mol Life Sci* 61, 973-981.

Gibb EA, Brown CJ & Lam WL (2011) The functional role of long non-coding RNA in human carcinomas. *Mol Cancer* 10, 38.

Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF & Van't Veer LJ (2006) Converting a breast cancer microarray signature into a high-throughput diagnostic test. *BMC Genomics* 7, 278.

Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD & Lander ES (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* 286, 531-537.

Gray LJ & Herrington CS (2004) Molecular markers for the prediction of progression of CIN lesions. *International journal of gynecological pathology* 23, 95-96.

Guelaguetza Vázquez-Ortíz ea (2005) Análisis de expresión global del cáncer cérvico uterino: rutas metabólicas y genes alterados. *Revista de Investigaciones Clinicas* 57 434-441.

Haffty BG & Glazer PM (2003) Molecular markers in clinical radiation oncology. *Oncogene* 22, 5915-5925.

Hanahan D & Weinberg RA (2000) The hallmarks of cancer. *Cell* 100, 57-70.

Hanson JC, Tangrea MA, Kim S, Armani MD, Pohida TJ, Bonner RF, Rodriguez-Canales J & Emmert-Buck MR (2011) Expression microdissection adapted to commercial laser dissection instruments. *Nature protocols* 6, 457-467.

Harima Y, Sawada S, Miyazaki Y, Kin K, Ishihara H, Imamura M, Sougawa M, Shikata N & Ohnishi T (2003) Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. *American journal of clinical oncology* 26, e80-85.

Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y & Katagiri T (2004) Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. *International journal of radiation oncology, biology, physics* 60, 237-248.

Harrell JC, Dye WW, Harvell DM, Sartorius CA & Horwitz KB (2008) Contaminating cells alter gene signatures in whole organ versus laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. *Clinical & experimental metastasis* 25, 81-88.

Harrison PR, Conkie D, Paul J & Jones K (1973) Localisation of cellular globin messenger RNA by in situ hybridisation to complementary DNA. *FEBS letters* 32, 109-112.

Hassan R, Bera T & Pastan I (2004) Mesothelin: a new target for immunotherapy. *Clinical cancer research* 10, 3937-3942.

Helliwell TR (2001) Molecular markers of metastasis in squamous carcinomas. *The Journal of pathology* 194, 289-293.

Hipp J, Cheng J, Hanson JC, Yan W, Taylor P, Hu N, Rodriguez-Canales J, Tangrea MA, Emmert-Buck MR & Balis U (2011) SIVQ-aided laser capture microdissection: A tool for high-throughput expression profiling. *Journal of pathology informatics* 2, 19.

Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM & Wolf E (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? *Cancer research* 61, 8601-8610.

Hollestelle A & Schutte M (2005) Representational difference analysis as a tool in the search for new tumor suppressor genes. *Methods in molecular medicine* 103, 143-159.

Hubank M & Schatz DG (1994) Identifying differences in mRNA expression by representational difference analysis of cDNA. *Nucleic Acids Research* 22, 5640-5648.

Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E & Manavi M (2005) cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study. *Cancer genetics and cytogenetics* 158, 35-42.

Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai HY, He YDD, Stephaniants SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, Blanchard AP, Friend SH & Linsley PS (2001) Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. *Nature Biotechnology* 19, 342-347.

Human Genome Sequencing C (2004) Finishing the euchromatic sequence of the human genome. *Nature* 431, 931-945.

Hwang J, Kim YY, Huh S, Shim J, Park C, Kimm K, Choi DK, Park TK & Kim S (2005) The time-dependent serial gene response to Zeocin treatment involves caspase-dependent apoptosis in HeLa cells. *Microbiology and immunology* 49, 331-342.

Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, van Lienen E, Inaji H, Van't Veer LJ & Kato K (2010) Clinical utility of the 70-gene MammaPrint profile in a Japanese population. *Japanese journal of clinical oncology* 40, 508-512.

Kalantari M, Garcia-Carranca A, Morales-Vazquez CD, Zuna R, Montiel DP, Calleja-Macias IE, Johansson B, Andersson S & Bernard HU (2009) Laser capture microdissection of cervical human papillomavirus infections: copy number of the virus in cancerous and normal tissue and heterogeneous DNA methylation. *Virology* 390, 261-267.

Keating JT, Ince T & Crum CP (2001) Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. *Advances in anatomic pathology* 8, 83-92.

Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? *International journal of cancer* 119, 243-250.

Kelley ML, Keiger KE, Lee CJ & Huibregtse JM (2005) The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. *Journal of virology* 79, 3737-3747.

Kent WJ (2002) BLAT--the BLAST-like alignment tool. *Genome research* 12, 656-664.

Kitahara O, Katagiri T, Tsunoda T, Harima Y & Nakamura Y (2002) Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. *Neoplasia* 4, 295-303.

Kitano H (2002) Systems biology: a brief overview. *Science* 295, 1662-1664.

Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer P & von Knebel Doeberitz M (1999) Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. *Cancer research* 59, 6132-6136.

Klee EW, Erdogan S, Tillmans L, Kosari F, Sun Z, Wigle DA, Yang P, Aubry MC & Vasmatzis G (2009) Impact of sample acquisition and linear amplification on gene expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-sampling versus bulk tissue-sampling. *BMC medical genomics* 2, 13.

Lander ES & Weinberg RA (2000) Genomics: journey to the center of biology. *Science* 287, 1777-1782.

Lazo PA (1999) The molecular genetics of cervical carcinoma. *British journal of cancer* 80, 2008-2018.

Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL & Zempolich KA (2006) Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines. *Clinical cancer research* 12, 250-256.

Lee KA, Shim JH, Kho CW, Park SG, Park BC, Kim JW, Lim JS, Choe YK, Paik SG & Yoon DY (2004) Protein profiling and identification of modulators regulated by the E7 oncogene in the C33A cell line by proteomics and genomics. *Proteomics* 4, 839-848.

Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, Bergeron J, Borchers C, Corthals GL, Costello CE, Deutsch EW, Domon B, Hancock W, He F, Hochstrasser D, Marko-Varga G, Salekdeh GH, Sechi S, Snyder M, Srivastava S, Uhlen M, Hu CH, Yamamoto T, Paik YK & Omenn GS (2011) The human proteome project: Current state and future direction. *Molecular & cellular proteomics*.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH & Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 275, 1943-1947.

Liang P & Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. *Science* 257, 967-971.

Liang P & Pardee AB (2003) Analysing differential gene expression in cancer. *Nature Reviews Cancer* 3, 869-876.

Lin J & Li M (2008) Molecular profiling in the age of cancer genomics. *Expert review of molecular diagnostics* 8, 263-276.

Liu SS, Cheung AN & Ngan HY (2003) Differential gene expression in cervical cancer cell lines before and after ionizing radiation. *International journal of oncology* 22, 1091-1099.

Lockhart DJ, Dong HL, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang CW, Kobayashi M, Horton H & Brown EL (1996) Expression monitoring by hybridization to high-density oligonucleotide arrays. *Nature Biotechnology* 14, 1675-1680.

Lu X, Toki T, Konishi I, Nikaido T & Fujii S (1998) Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. *Cancer* 82, 2409-2417.

Macoska JA (2002) The progressing clinical utility of DNA microarrays. *CA Cancer J Clin* 52, 50-59.

Martin CM, Astbury K & O'Leary JJ (2006) Molecular profiling of cervical neoplasia. *Expert review of molecular diagnostics* 6, 217-229.

Mendes Soares LM & Valcarcel J (2006) The expanding transcriptome: the genome as the 'Book of Sand'. *The EMBO Journal* 25, 923-931.

Mikheev AM, Mikheeva SA, Liu B, Cohen P & Zarbl H (2004) A functional genomics approach for the identification of putative tumor suppressor genes: Dickkopf-1 as suppressor of HeLa cell transformation. *Carcinogenesis* 25, 47-59.

Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET & Van't Veer LJ (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. *Breast cancer research and treatment* 116, 295-302.

Nees M, Geoghegan JM, Hyman T, Frank S, Miller L & Woodworth CD (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. *Journal of virology* 75, 4283-4296.

Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E & Woodworth CD (2000) Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes. *Cancer research* 60, 4289-4298.

Nees M, van Wijngaarden E, Bakos E, Schneider A & Durst M (1998) Identification of novel molecular markers which correlate with HPV-induced tumor progression. *Oncogene* 16, 2447-2458.

Ng P, Wei CL, Sung WK, Chiu KP, Lipovich L, Ang CC, Gupta S, Shahab A, Ridwan A, Wong CH, Liu ET & Ruan Y (2005) Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. *Nature Methods* 2, 105-111.

Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E & Gau CH (2005) Is p16(INK4A) expression more useful than human papillomavirus test to determine the outcome of atypical

squamous cells of undetermined significance-categorized Pap smear? A comparative analysis using abnormal cervical smears with follow-up biopsies. *Gynecologic oncology* 97, 35-40.

Nisole S, Stoye JP & Saib A (2005) TRIM family proteins: retroviral restriction and antiviral defence. *Nature Reviews Microbiology* 3, 799-808.

Novina CD & Sharp PA (2004) The RNAi revolution. *Nature* 430, 161-164.

Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB & Herman JG (1999) In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. *Proceedings of the National Academy of Sciences of the United States of America* 96, 12754-12759.

Okamoto K & Beach D (1994) Cyclin-G Is a Transcriptional Target of the P53 Tumor-Suppressor Protein. *The EMBO Journal* 13, 4816-4822.

Orlando V (2000) Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation. *Trends in Biochemical Sciences* 25, 99-104.

Perez-Plasencia C, Riggins G, Vazquez-Ortiz G, Moreno J, Arreola H, Hidalgo A, Pina-Sanchez P & Salcedo M (2005) Characterization of the global profile of genes expressed in cervical epithelium by Serial Analysis of Gene Expression (SAGE). *BMC Genomics* 6, 130.

Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, Stanley MA & Coleman N (2006) Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. *Proceedings of the National Academy of Sciences of the United States of America* 103, 3822-3827.

Polyak K & Riggins GJ (2001) Gene discovery using the serial analysis of gene expression technique: Implications for cancer research. *Journal of Clinical Oncology* 19, 2948-2958.

Quackenbush J (2004) Data standards for 'omic' science. *Nature Biotechnology* 22, 613-614.

Ramaswamy S, Ross KN, Lander ES & Golub TR (2003) A molecular signature of metastasis in primary solid tumors. *Nature Genetics* 33, 49-54.

Ranamukhaarachchi DG, Unger ER, Vernon SD, Lee D & Rajeevan MS (2005) Gene expression profiling of dysplastic differentiation in cervical epithelial cells harboring human papillomavirus 16. *Genomics* 85, 727-738.

Rappolee DA, Mark D, Banda MJ & Werb Z (1988) Wound macrophages express TGF-alpha and other growth factors in vivo: analysis by mRNA phenotyping. *Science* 241, 708-712.

Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, Hannett N, Kanin E, Volkert TL, Wilson CJ, Bell SP & Young RA (2000) Genome-wide location and function of DNA binding proteins. *Science* 290, 2306-+.

Rhodes DR & Chinnaiyan AM (2005) Integrative analysis of the cancer transcriptome. *Nature Genetics* 37, S31-S37.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T & Staudt LM (2002) The use of

molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *The New England journal of medicine* 346, 1937-1947.

Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La Rochefordiere A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany E & Sastre-Garau X (2005) Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. *Oncogene* 24, 7094-7104.

Ruutu M, Peitsaro P, Johansson B & Syrjanen S (2002) Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. *International journal of cancer* 100, 318-326.

Sakakura C, Hagiwara A, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ito K, Yamagishi H, Yazumi S, Chiba T & Ito Y (2005) Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. *International journal of cancer* 113, 221-228.

Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Jr. & Pecorelli S (2005) Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. *Virology* 331, 269-291.

Schena M, Shalon D, Davis RW & Brown PO (1995) Quantitative Monitoring of Gene-Expression Patterns with a Complementary-DNA Microarray. *Science* 270, 467-470.

Segal E, Friedman N, Kaminski N, Regev A & Koller D (2005) From signatures to models: understanding cancer using microarrays. *Nature Genetics* 37 Suppl, S38-45.

Seo MJ, Bae SM, Kim YW, Hur SY, Ro DY, Lee JM, Namkoong SE, Kim CK & Ahn WS (2005) New approaches to pathogenic gene function discovery with human squamous cell cervical carcinoma by gene ontology. *Gynecologic oncology* 96, 621-629.

Sgarlato GD, Eastman CL & Sussman HH (2005) Panel of genes transcriptionally up-regulated in squamous cell carcinoma of the cervix identified by representational difference analysis, confirmed by macroarray, and validated by real-time quantitative reverse transcription-PCR. *Clinical chemistry* 51, 27-34.

Shapiro JA (2009) Revisiting the central dogma in the 21st century. *Annals of the New York Academy of Sciences* 1178, 6-28.

Sherman ME (2003) Chapter 11: Future directions in cervical pathology. *Journal of the National Cancer Institute. Monographs*, 72-79.

Sherman ME & Kurman RJ (1998) Intraepithelial carcinoma of the cervix: reflections on half a century of progress. *Cancer* 83, 2243-2246.

Shim C, Zhang W, Rhee CH & Lee JH (1998) Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. *Clinical cancer research* 4, 3045-3050.

Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC & Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nature medicine* 8, 68-74.

Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta LA, Petricoin EF & Pierobon M (2010) Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. *Laboratory investigation; a journal of technical methods and pathology* 90, 787-796.

Singh-Gasson S, Green RD, Yue Y, Nelson C, Blattner F, Sussman MR & Cerrina F (1999) Maskless fabrication of light-directed oligonucleotide microarrays using a digital micromirror array. *Nature Biotechnology* 17, 974-978.

Slodkowska EA & Ross JS (2009) MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. *Expert review of molecular diagnostics* 9, 417-422.

Snijders PJ, Steenbergen RD, Heideman DA & Meijer CJ (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. *The Journal of pathology* 208, 152-164.

Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R, Kirchmayr R, Schneider A & Durst M (2004) Detection of cancer-related gene expression profiles in severe cervical neoplasia. *International journal of cancer* 112, 33-43.

Southan C (2004) Has the yo-yo stopped? An assessment of human protein-coding gene number. *Proteomics* 4, 1712-1726.

Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A & Kiviat N (2006) Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. *Cancer epidemiology, biomarkers & prevention* 15, 114-123.

Stein LD (2004) Human genome: end of the beginning. *Nature* 431, 915-916.

Steinau M, Lee DR, Rajeevan MS, Vernon SD, Ruffin MT & Unger ER (2005) Gene expression profile of cervical tissue compared to exfoliated cells: impact on biomarker discovery. *BMC Genomics* 6, 64.

Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ & Marra MA (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proceedings of the National Academy of Sciences of the United States of America* 99, 16899-16903.

Strebhardt K & Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. *Nature Reviews Cancer* 6, 321-330.

Tangrea MA, Chuaqui RF, Gillespie JW, Ahram M, Gannot G, Wallis BS, Best CJ, Linehan WM, Liotta LA, Pohida TJ, Bonner RF & Emmert-Buck MR (2004) Expression microdissection: operator-independent retrieval of cells for molecular profiling. *Diagnostic molecular pathology* 13, 207-212.

Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA & Fruehauf JP (2005) Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study. *Gynecologic oncology* 99, 84-91.

Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S & Desaintes C (2004) A genomic approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. *Cancer research* 64, 895-903.

Thomas JT, Oh ST, Terhune SS & Laimins LA (2001) Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. *Journal of virology* 75, 7564-7571.

Thorgeirsson SS, Lee JS & Grisham JW (2006) Functional genomics of hepatocellular carcinoma. *Hepatology* 43, S145-150.

Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F & Glas AM (2010) Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. *Biomark Insights* 5, 129-138.

Toussaint-Smith E, Donner DB & Roman A (2004) Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. *Oncogene* 23, 2988-2995.

Usmani N, Foroudi F, Du J, Zakos C, Campbell H, Bryson P & Mackillop WJ (2005) An evidence-based estimate of the appropriate rate of utilization of radiotherapy for cancer of the cervix. *International journal of radiation oncology, biology, physics* 63, 812-827.

van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R & Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415, 530-536.

van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH & Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. *The New England journal of medicine* 347, 1999-2009.

Vazquez-Ortiz G, Ciudad CJ, Pina P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, Salamanca F, Peralta-Rodriguez R, Rangel A & Salcedo M (2005a) Gene identification by cDNA arrays in HPV-positive cervical cancer. *Archives of medical research* 36, 448-458.

Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA & Salcedo M (2005b) Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. *BMC Cancer* 5, 68.

Velculescu VE, Zhang L, Vogelstein B & Kinzler KW (1995) Serial Analysis of Gene-Expression. *Science* 270, 484-487.

Vogelstein B & Kinzler KW (2004) Cancer genes and the pathways they control. *Nature medicine* 10, 789-799.

Wadlow R & Ramaswamy S (2005) DNA microarrays in clinical cancer research. *Current molecular medicine* 5, 111-120.

Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK & Povey S (2004) Genew: the Human Gene Nomenclature Database, 2004 updates. *Nucleic Acids Research* 32, D255-257.

Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu YT, Weng ZP, Liu JJ, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH & Ruan YJ (2006) A global map of p53 transcription-factor binding sites in the human genome. *Cell* 124, 207-219.

Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA & Howley PM (2003) Transcriptome signature of irreversible senescence in human papillomavirus-positive cervical cancer cells. *Proceedings of the National Academy of Sciences of the United States of America* 100, 7093-7098.

Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, Dicuccio M, Edgar R, Federhen S, Feolo M, Geer LY, Helmberg W, Kapustin Y, Khovayko O, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Ostell J, Pruitt KD, Schuler GD, Shumway M, Sequeira E, Sherry ST, Sirotkin K, Souvorov A, Starchenko G, Tatusov RL, Tatusova TA, Wagner L & Yaschenko E (2008) Database resources of the National Center for Biotechnology Information. *Nucleic Acids Research* 36, D13-21.

Whitfield ML, George LK, Grant GD & Perou CM (2006) Common markers of proliferation. *Nature Reviews Cancer* 6, 99-106.

Wilting SM, Snijders PJ, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM, Albertson DG, Coffa J, Schouten JP, van de Wiel MA, Meijer CJ & Steenbergen RD (2006) Increased gene copy numbers at chromosome 20q are frequent in both squamous cell carcinomas and adenocarcinomas of the cervix. *The Journal of pathology* 209, 220-230.

Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan SC, Chan LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK & Smith DI (2006) Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. *International journal of cancer* 118, 2461-2469.

Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina E, McKinnon RD, Denhardt DT, Chin KV & Chung TK (2003) Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. *Clinical cancer research* 9, 5486-5492.

Woodman CBJ, Collins SI & Young LS (2007) The natural history of cervical HPV infection: unresolved issues. *Nature Reviews Cancer* 7, 11-22.

Woodworth CD, Michael E, Marker D, Allen S, Smith L & Nees M (2005) Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. *Molecular cancer therapeutics* 4, 650-658.

Yamashita T, Honda M & Kaneko S (2008) Application of Serial Analysis of Gene Expression in cancer research. *Current pharmaceutical biotechnology* 9, 375-382.

Yen CC, Chen YJ, Pan CC, Lu KH, Chen PC, Hsia JY, Chen JT, Wu YC, Hsu WH, Wang LS, Huang MH, Huang BS, Hu CP, Chen PM & Lin CH (2005) Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed. *World journal of gastroenterology : WJG* 11, 1267-1272.

Yim EK & Park JS (2006) Role of proteomics in translational research in cervical cancer. *Expert review of proteomics* 3, 21-36.

Yuan J, Yan R, Kramer A, Eckerdt F, Roller M, Kaufmann M & Strebhardt K (2004) Cyclin B1
        depletion inhibits proliferation and induces apoptosis in human tumor cells.
        Oncogene 23, 5843-5852.
Zimmermann CR, Orr WC, Leclerc RF, Barnard EC & Timberlake WE (1980) Molecular
        cloning and selection of genes regulated in Aspergillus development. *Cell* 21, 709-
        715.
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application.
        Nature Reviews Cancer 2, 342-350.
zur Hausen H (2009) The search for infectious causes of human cancers: Where and why
        (Nobel lecutre). *Angewandte Chemie International Edition* 48, 5798-5808.

Topics on Cervical Cancer With an Advocacy for Prevention
Edited by Dr. R. Rajamanickam

Cervical Cancer is one of the leading cancers among women, especially in developing countries. Prevention and control are the most important public health strategies. Empowerment of women, education, "earlier" screening by affordable technologies like visual inspection, and treatment of precancers by cryotherapy/ LEEP are the most promising interventions to reduce the burden of cervical cancer.Dr Rajamanickam Rajkumar had the privilege of establishing a rural population based cancer registry in South India in 1996, as well as planning and implementing a large scale screening program for cervical cancer in 2000. The program was able to show a reduction in the incidence rate of cervical cancer by 25%, and reduction in mortality rate by 35%. This was the greatest inspiration for him to work on cerrvical cancer prevention, and he edited this book to inspire others to initiate such programs in developing countries. InTech - Open Access Publisher plays a major role in this crusade against cancer, and the authors have contributed to it very well.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Carlos G. Acevedo-Rocha, José A. Munguía-Moreno, Rodolfo Ocádiz-Delgado and Patricio Gariglio (2012). A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer, Topics on Cervical Cancer With an Advocacy for Prevention, Dr. R. Rajamanickam (Ed.), ISBN: 978-953-51-0183-3, InTech, Available from: http://www.intechopen.com/books/topics-on-cervical-cancer-with-an-advocacy-for-prevention/a-transcriptome-and-marker-based-systematic-analysis-of-cervical-cancer

INTECH
open science | open minds